<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">28768</article-id><article-id pub-id-type="doi">10.7554/eLife.28768</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-88944"><name><surname>Chua</surname><given-names>Chee Wai</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9634-7265</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="pa2">‡</xref></contrib><contrib contrib-type="author" id="author-88951"><name><surname>Epsi</surname><given-names>Nusrat J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5363-075X</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-101733"><name><surname>Leung</surname><given-names>Eva Y</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1291-6625</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-101734"><name><surname>Xuan</surname><given-names>Shouhong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0571-7855</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-88946"><name><surname>Lei</surname><given-names>Ming</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-88947"><name><surname>Li</surname><given-names>Bo I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4104-4179</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-88948"><name><surname>Bergren</surname><given-names>Sarah K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-88949"><name><surname>Hibshoosh</surname><given-names>Hanina</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-88950"><name><surname>Mitrofanova</surname><given-names>Antonina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0671-6512</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-27341"><name><surname>Shen</surname><given-names>Michael M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4042-1657</contrib-id><email>mshen@columbia.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Medicine</institution><institution>Columbia University Medical Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Genetics and Development</institution><institution>Columbia University Medical Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Urology</institution><institution>Columbia University Medical Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Systems Biology</institution><institution>Columbia University Medical Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Herbert Irving Comprehensive Cancer Center</institution><institution>Columbia University Medical Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Department of Health Informatics, Rutgers School of Health Professions</institution><institution>Rutgers, The State University of New Jersey</institution><addr-line><named-content content-type="city">Newark</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Rutgers Biomedical and Health Sciences</institution><institution>Rutgers, The State University of New Jersey</institution><addr-line><named-content content-type="city">Newark</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">Department of Pathology and Cell Biology</institution><institution>Columbia University Medical Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1146"><name><surname>Morrison</surname><given-names>Sean J</given-names></name><role>Reviewing Editor</role><aff id="aff9"><institution>Howard Hughes Medical Institute, University of Texas Southwestern Medical Center</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>15</day><month>01</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e28768</elocation-id><history><date date-type="received" iso-8601-date="2017-05-18"><day>18</day><month>05</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2018-01-12"><day>12</day><month>01</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Chua et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Chua et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-28768-v3.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.28768.001</object-id><p>Master regulatory genes of tissue specification play key roles in stem/progenitor cells and are often important in cancer. In the prostate, androgen receptor (AR) is a master regulator essential for development and tumorigenesis, but its specific functions in prostate stem/progenitor cells have not been elucidated. We have investigated AR function in CARNs (CAstration-Resistant Nkx3.1-expressing cells), a luminal stem/progenitor cell that functions in prostate regeneration. Using genetically--engineered mouse models and novel prostate epithelial cell lines, we find that progenitor properties of CARNs are largely unaffected by AR deletion, apart from decreased proliferation <italic>in vivo</italic>. Furthermore, AR loss suppresses tumor formation after deletion of the <italic>Pten</italic> tumor suppressor in CARNs; however, combined <italic>Pten</italic> deletion and activation of oncogenic <italic>Kras</italic> in AR-deleted CARNs result in tumors with focal neuroendocrine differentiation. Our findings show that AR modulates specific progenitor properties of CARNs, including their ability to serve as a cell of origin for prostate cancer.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.28768.002</object-id><title>eLife digest</title><p>Most prostate tumors rely on male hormones – called androgens – to survive. Aggressive prostate cancer is often treated with drugs that block androgens, which usually cause the prostate tumors to shrink. One class of the drugs works by binding to and inactivating the androgen receptor protein on prostate cancer cells. However, aggressive prostate tumors can often become resistant to these anti-androgen therapies.</p><p>It is not clear where the resistant cancer cells come from. In 2009, researchers showed that the normal prostate contains some cells that appear to be independent of androgens. A subset of these cells – also known as CARNs – can act as stem or progenitor cells that can repair the prostate after injury. These normal androgen-independent cells can also be the cells from which prostate tumors arise. Here, Chua et al. – including one of the researchers from the 2009 study – investigated how these CARN cells behave when the androgen receptor is deleted.</p><p>When the androgen receptor was genetically removed in CARN cells of otherwise healthy mice, the behavior of CARN cells was unaffected. When the androgen receptor was deleted together with a protein that normally suppresses the formation of tumors, it protected the mice from prostate cancer. However, Chua et al. also observed that deleting the androgen receptor could not prevent the tumor from growing when two cancer-causing mutations were present. These tumors were similar to human prostate tumors that are resistant to anti-androgen therapy.</p><p>Since CARN cells may also exist in humans, this new way of making prostate cancers in mice may be used to study how these resistances arise in patients. A better understanding of how prostate tumors develop might lead to new treatments in which the androgen receptor is blocked in combination with other new protein targets.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>prostate</kwd><kwd>progenitor</kwd><kwd>androgen receptor</kwd><kwd>cell of origin</kwd><kwd>mouse models</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK076602</award-id><principal-award-recipient><name><surname>Shen</surname><given-names>Michael M</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>CA1966692</award-id><principal-award-recipient><name><surname>Shen</surname><given-names>Michael M</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>Prostate Cancer Research Program PC101820</award-id><principal-award-recipient><name><surname>Chua</surname><given-names>Chee Wai</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>Prostate Cancer Research Program PC141064</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Bo I</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000892</institution-id><institution>Prostate Cancer Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Shen</surname><given-names>Michael M</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Rutgers SHP Dean's Intramural Grant</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Mitrofanova</surname><given-names>Antonina</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Analyses of genetically engineered mouse models reveal the androgen receptor-independent properties of a luminal stem/progenitor cell in the prostate epithelium, and its ability to serve as a cell of origin for castration-resistant prostate cancer.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Elucidating the cell type(s) of origin of cancer and the molecular drivers of tumor initiation is of fundamental importance in understanding the basis of distinct tumor subtypes as well as differences in treatment response and patient outcomes (<xref ref-type="bibr" rid="bib9">Blanpain, 2013</xref>; <xref ref-type="bibr" rid="bib42">Rycaj and Tang, 2015</xref>; <xref ref-type="bibr" rid="bib44">Shibata and Shen, 2013</xref>; <xref ref-type="bibr" rid="bib51">Visvader, 2011</xref>). Furthermore, since cancer often originates from stem cells and/or lineage-restricted progenitor cells, the identification of stem/progenitor cells is of considerable significance. In the case of the prostate, however, both the specific identity of stem/progenitor cells as well as cell types of origin for cancer have remained unclear (<xref ref-type="bibr" rid="bib31">Lee and Shen, 2015</xref>; <xref ref-type="bibr" rid="bib55">Wang and Shen, 2011</xref>; <xref ref-type="bibr" rid="bib60">Xin, 2013</xref>).</p><p>In the normal prostate epithelium, there are three primary cell types, corresponding to secretory luminal cells, an underlying layer of basal cells, and rare neuroendocrine cells (<xref ref-type="bibr" rid="bib43">Shen and Abate-Shen, 2010</xref>; <xref ref-type="bibr" rid="bib50">Toivanen and Shen, 2017</xref>). Lineage-tracing studies have shown that both luminal and basal cells are mostly lineage-restricted (unipotent) in the normal adult mouse prostate as well as during androgen-mediated prostate regeneration (<xref ref-type="bibr" rid="bib12">Choi et al., 2012</xref>; <xref ref-type="bibr" rid="bib34">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Lu et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Wang et al., 2013</xref>). In addition, cells within the basal compartment possess stem/progenitor properties in a range of ex vivo assays as well as during inflammation and wound repair (<xref ref-type="bibr" rid="bib21">Goldstein et al., 2008</xref>; <xref ref-type="bibr" rid="bib24">Höfner et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Kwon et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Lawson et al., 2007</xref>; <xref ref-type="bibr" rid="bib49">Toivanen et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Wang et al., 2013</xref>). However, recent studies have shown that luminal cells can also display stem/progenitor properties in specific <italic>in vivo</italic> and <italic>ex vivo</italic> contexts (<xref ref-type="bibr" rid="bib13">Chua et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Karthaus et al., 2014</xref>; <xref ref-type="bibr" rid="bib29">Kwon et al., 2016</xref>; <xref ref-type="bibr" rid="bib53">Wang et al., 2009</xref>). Furthermore, there is now considerable evidence supporting a luminal origin for prostate cancer, both in mouse models (<xref ref-type="bibr" rid="bib53">Wang et al., 2009</xref>; <xref ref-type="bibr" rid="bib56">Wang et al., 2014</xref>) as well as in human tissues (<xref ref-type="bibr" rid="bib22">Gurel et al., 2008</xref>; <xref ref-type="bibr" rid="bib36">Meeker et al., 2002</xref>).</p><p>Androgen receptor (AR) plays a central role in many aspects of normal prostate development as well as prostate cancer progression (<xref ref-type="bibr" rid="bib14">Cunha et al., 2004</xref>; <xref ref-type="bibr" rid="bib50">Toivanen and Shen, 2017</xref>; <xref ref-type="bibr" rid="bib57">Watson et al., 2015</xref>). In the prostate epithelium of adult hormonally intact mice, AR is primarily expressed by luminal cells, but is also found in a subset of basal cells (<xref ref-type="bibr" rid="bib32">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="bib37">Mirosevich et al., 1999</xref>; <xref ref-type="bibr" rid="bib59">Xie et al., 2017</xref>). Several studies have shown that conditional deletion of AR in the adult prostate epithelium results in a short-term increase in proliferation of luminal cells (<xref ref-type="bibr" rid="bib58">Wu et al., 2007</xref>; <xref ref-type="bibr" rid="bib59">Xie et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Zhang et al., 2016a</xref>), indicating a role for AR in normal prostate homeostasis. Importantly, AR can act as a master regulator of prostate epithelial specification in a fibroblast reprogramming assay (<xref ref-type="bibr" rid="bib48">Talos et al., 2017</xref>).</p><p>In the context of prostate cancer, tumor recurrence after androgen-deprivation therapy is due to the emergence of castration-resistant prostate cancer (CRPC), which is associated with increased AR activity that can be targeted by second-generation anti-androgen therapies (<xref ref-type="bibr" rid="bib57">Watson et al., 2015</xref>). However, treatment failure following such anti-androgen therapies is frequently associated with the appearance of AR-negative tumor cells, which are typically associated with highly aggressive lethal disease (<xref ref-type="bibr" rid="bib6">Beltran et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Vlachostergios et al., 2017</xref>; <xref ref-type="bibr" rid="bib57">Watson et al., 2015</xref>). In some cases, this AR-negative CRPC contain large regions displaying a neuroendocrine phenotype (CRPC-NE) (<xref ref-type="bibr" rid="bib4">Beltran et al., 2016</xref>, <xref ref-type="bibr" rid="bib6">2014</xref>; <xref ref-type="bibr" rid="bib27">Ku et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Mu et al., 2017</xref>; <xref ref-type="bibr" rid="bib66">Zou et al., 2017</xref>).</p><p>Previous work from our laboratory has identified CARNs as a luminal stem/progenitor cell within the androgen-deprived normal mouse prostate epithelium that is also a cell of origin for prostate cancer (<xref ref-type="bibr" rid="bib53">Wang et al., 2009</xref>). Following androgen administration to induce prostate regeneration, CARNs can generate both luminal and basal progeny <italic>in vivo</italic>, as well as in renal grafting and organoid assays (<xref ref-type="bibr" rid="bib13">Chua et al., 2014</xref>; <xref ref-type="bibr" rid="bib53">Wang et al., 2009</xref>). Although CARNs express AR (<xref ref-type="bibr" rid="bib53">Wang et al., 2009</xref>), it has been unclear whether AR is required for any or all the progenitor properties of CARNs, and whether the intrinsic castration-resistance of untransformed CARNs might resemble the castration-resistance of tumor cells in CRPC. Below, we show that the progenitor properties of CARNs are largely unaffected by loss of AR, whereas their ability to serve as cells of origin for prostate cancer are altered by AR deletion in a context-dependent manner. Notably, cell lines derived from AR-deleted CARNs have molecular profiles that resemble those for CRPC, and AR-deleted CARNs can serve as a cell of origin for focal neuroendocrine differentiation in a novel mouse model of AR-negative prostate cancer.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>To investigate whether the stem/progenitor properties of CARNs are dependent upon AR function, we have used an inducible targeting approach in genetically engineered mice. For this purpose, we used mice carrying a conditional allele of <italic>Ar</italic> (<xref ref-type="bibr" rid="bib15">De Gendt et al., 2004</xref>) together with the inducible <italic>Nkx3.1<sup>CreERT2</sup></italic> driver (<xref ref-type="bibr" rid="bib53">Wang et al., 2009</xref>) and the <italic>R26R-YFP</italic> reporter to visualize cells and their progeny in which Cre-mediated recombination has taken place (<xref ref-type="bibr" rid="bib45">Srinivas et al., 2001</xref>); as <italic>Ar</italic> is an X-linked gene, deletion of a single allele in males is sufficient to confer a hemizygous null phenotype. Since CARNs are Nkx3.1-expressing cells found under androgen-deprived conditions, we castrated adult male mice carrying the Cre driver and reporter alleles, followed by tamoxifen induction to induce Cre-mediated activity specifically in CARNs (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.28768.003</object-id><label>Figure 1.</label><caption><title>CARNs remain luminal after AR deletion.</title><p>(<bold>A</bold>) Time course for lineage-marking of CARNs and inducible <italic>AR</italic> deletion using castrated and tamoxifen-treated control <italic>Nkx3.1<sup>CreERT2/+</sup>; R26R-YFP/+</italic> mice and <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice. (<bold>B</bold>) FACS analyses of lineage-marked YFP<sup>+</sup> cells in total EpCAM<sup>+</sup> epithelial cells. (<bold>C</bold>) Percentage of YFP<sup>+</sup> cells among total epithelial cells in castrated and tamoxifen-induced <italic>Nkx3.1<sup>CreERT2/+</sup>; R26R-YFP/+</italic> controls and <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice. Error bars represent one standard deviation; the difference between groups is not significant (p=0.51, independent t-test). (<bold>D</bold>) Expression of AR, luminal markers (CK8 and CK18), and basal markers (CK5 and p63) in lineage-marked CARNs (top) and AR-deleted CARNs (bottom). Note that all lineage-marked cells express luminal but not basal markers (arrows). Scale bars in <bold>D</bold>) correspond to 50 μm.</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.28768.004</object-id><label>Figure 1—source data 1.</label><caption><title>Quantitation of CARNs and AR-deleted CARNs <italic>in vivo</italic>.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-28768-fig1-data1-v3.docx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-28768-fig1-v3"/></fig><p>Using this strategy, we compared the properties of CARNs in <italic>Nkx3.1<sup>CreERT2/+</sup>; R26R-YFP/+</italic> mice, which we denote as ‘control’ mice, with those in <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice, which we denote as ‘AR-deleted’ mice. We found that the percentage of lineage-marked YFP-positive cells, corresponding to CARNs, was not significantly different (p=0.51) between the control (0.36 ± 0.17%, n = 5 mice) and AR-deleted mice (0.31 ± 0.06%, n = 5 mice) (<xref ref-type="fig" rid="fig1">Figure 1B,C</xref>). Notably, we found that 87.1% of the YFP-positive cells in <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice (n = 344/395 cells in four mice) were AR-negative, indicating that AR deletion occurred with high efficiency. Furthermore, these YFP-positive cells expressed the luminal markers cytokeratins 8 and 18 (CK8 and CK18), but not cytokeratin 5 (CK5) and p63, indicating that AR deletion does not alter the luminal phenotype of CARNs (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). These findings indicate that AR deletion does not affect the frequency or luminal properties of CARNs.</p><p>To investigate the progenitor properties of AR-deleted CARNs, we examined their ability to generate progeny during androgen-mediated regeneration. We implanted subcutaneous mini-osmotic pumps containing testosterone into control <italic>Nkx3.1<sup>CreERT2/+</sup>; R26R-YFP/+</italic> mice as well as <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice, followed by tissue harvest at 4, 7, 14, and 28 days later; the final 28-day time point corresponds to a fully regenerated prostate (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We found that the YFP-marked cells and cell clusters were similar in the control and AR-deleted prostates at 4 and 7 days after testosterone administration (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>). However, at 14 and 28 days, the control prostates contained many YFP-expressing cell clusters with more than 4 cells, whereas the prostates with AR-deleted CARNs mostly contained YFP-expressing single cells or doublets (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>).</p><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.28768.005</object-id><label>Figure 2.</label><caption><title>AR-deleted CARNs fail to generate lineage-marked cell clusters but remain bipotential during androgen-mediated regeneration.</title><p>(<bold>A</bold>) Time course for lineage-marking and androgen-mediated regeneration. (<bold>B</bold>) Percentage of single YFP<sup>+</sup> cells or YFP<sup>+</sup> clusters of 2 cells, 3–4 cells, and &gt;4 cells at 4, 7, 14, and 28 days of androgen-mediated regeneration. This analysis does not include YFP<sup>+</sup>AR<sup>+</sup> cells that fail to undergo AR deletion in the experimental mice; full quantitation of all cell populations is provided in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. (<bold>C</bold>) YFP<sup>+</sup> cells (arrows) in prostates of mice with lineage-marked CARNs (top) and AR-deleted CARNs (bottom) at days 4, 7, 14 and 28 days during androgen-mediated regeneration. (<bold>D</bold>) Identification of basal YFP<sup>+</sup> cells (arrows) as progeny of CARNs (top) or AR-deleted CARNs (bottom). Scale bars in <bold>C</bold>) and <bold>D</bold>) correspond to 50 μm.</p><p><supplementary-material id="fig2sdata1"><object-id pub-id-type="doi">10.7554/eLife.28768.006</object-id><label>Figure 2—source data 1.</label><caption><title>Quantitation of YFP<sup>+</sup> cells during regeneration.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-28768-fig2-data1-v3.docx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-28768-fig2-v3"/></fig><p>To compare the proliferative ability of control and AR-deleted CARNs and their progeny, we pursued BrdU pulse-chase experiments during prostate regeneration. We performed castration and tamoxifen administration on control and AR-deleted mice, followed by androgen-mediated regeneration for 28 days, with administration of daily doses of BrdU either from days 1 through 4 of regeneration or from days 11 through 14 (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>). When BrdU was administered from days 1 through 4 of regeneration, we could readily detect BrdU<sup>+</sup>YFP<sup>+</sup> cells in the control prostates (50.9 ± 11.8%, n = 3 mice) as well as AR-deleted prostates (62.9 ± 14.9%, n = 3 mice) (<xref ref-type="fig" rid="fig3">Figure 3C,E</xref>). In contrast, when BrdU was administered from days 11 through 14, we could only detect BrdU<sup>+</sup>YFP<sup>+</sup> cells in the control prostates (11.1 ± 6.2%, n = 3 mice), but not in the AR-deleted prostates (0%, n = 3 mice) (<xref ref-type="fig" rid="fig3">Figure 3D,F</xref>). This difference suggests that AR-deleted CARNs and/or their progeny have a defect in proliferation during later stages of regeneration, consistent with the analysis of YFP<sup>+</sup> cluster size (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.28768.007</object-id><label>Figure 3.</label><caption><title>AR-deleted CARNs and/or their progeny have defects in proliferation during regeneration and in renal grafts.</title><p>(<bold>A,B</bold>) Time course of BrdU incorporation during androgen-mediated regeneration of castrated and tamoxifen-treated control <italic>Nkx3.1<sup>CreERT2/+</sup>; R26R-YFP/+</italic> mice and <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice. BrdU injections were performed during either days 1 through 4 (<bold>A</bold>) or days 11 through 14 (<bold>B</bold>), followed by analysis at 28 days. (<bold>C</bold>) Identification of BrdU<sup>+</sup>YFP<sup>+</sup> cells (arrows) in control (top) and AR-deleted (bottom) prostate tissue after administration of BrdU during early stages of regeneration. (<bold>D</bold>) YFP-positive cells in control prostate tumors (top) can incorporate BrdU (arrow) but not in AR-deleted prostate tumors (bottom), after administration of BrdU during later stages of regeneration. (<bold>E,F</bold>) Percentage of BrdU<sup>+</sup> and BrdU<sup>–</sup> cells among total YFP<sup>+</sup> cells after injection of BrdU from days 1 through 4 (<bold>E</bold>) or days 11 through 14 (<bold>F</bold>) of regeneration. Error bars represent one standard deviation; the difference in (<bold>E</bold>) is not statistically significant (p=0.34, independent t-test), but is significant in (<bold>F</bold>) (p=0.027, independent t-test). This analysis excludes YFP<sup>+</sup>AR<sup>+</sup> cells that fail to undergo AR deletion in the experimental mice; full quantitation of all cell populations is provided in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>. (<bold>G</bold>) Schematic depiction of tissue recombination of lineage-marked CARNs with rat urogenital mesenchyme followed by renal grafting. (<bold>H</bold>) Analysis of grafts generated from lineage-marked CARNs (top) and AR-deleted CARNs (bottom); arrows in bottom panels indicate AR-expressing stromal cells surrounding the AR-negative prostate duct. Scale bars in <bold>C</bold>), <bold>D</bold>) and <bold>H</bold>) correspond to 50 μm.</p><p><supplementary-material id="fig3sdata1"><object-id pub-id-type="doi">10.7554/eLife.28768.008</object-id><label>Figure 3—source data 1.</label><caption><title>Quantitation of BrdU incorporation and renal grafting data.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-28768-fig3-data1-v3.docx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-28768-fig3-v3"/></fig><p>Notably, although YFP-expressing basal cells could be readily identified in both control and AR-deleted prostates, there was an increase in the percentage of basal cells within the YFP<sup>+</sup> population in the AR-deleted mice (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). This difference was evident using either the basal marker CK5 (2.1% CK5<sup>+</sup>AR<sup>+</sup>YFP<sup>+</sup> versus 19.2% CK5<sup>+</sup>AR<sup>–</sup>YFP<sup>+</sup>) or p63 (3.5% p63<sup>+</sup>AR<sup>+</sup>YFP<sup>+</sup> versus 14.6% p63<sup>+</sup>AR<sup>–</sup>YFP<sup>+</sup>) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). These findings indicate that AR-deleted CARNs favor generation of basal progeny and/or that there is decreased proliferation or survival of luminal progeny during regeneration.</p><p>As a further test of the progenitor properties of AR-deleted CARNs, we examined their ability to generate prostate ducts in a tissue recombination/renal grafting assay. Previously, we had shown that single CARNs were capable of generating ducts in this assay (<xref ref-type="bibr" rid="bib53">Wang et al., 2009</xref>). We isolated YFP-positive cells from control and AR-deleted mice that had undergone castration and tamoxifen induction, and recombined 10 YFP-positive cells together with 2.5 × 10<sup>5</sup> rat embryonic urogenital mesenchyme cells, followed by renal grafting (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). We found that both control and AR-deleted CARNs could generate prostate ducts (<xref ref-type="fig" rid="fig3">Figure 3H</xref>), but that the AR-deleted CARN-s were significantly less efficient (12.5% graft efficiency, n = 16) compared to the control CARNs (p=0.003; 68.8% graft efficiency, n = 16), consistent with a proliferation defect in the AR-deleted CARNs.</p><p>Based on these findings, we further investigated the properties of CARNs and AR-deleted CARNs by establishing adherent cell lines. Using a novel method based on conditions that we previously established for culture of prostate organoids (<xref ref-type="bibr" rid="bib13">Chua et al., 2014</xref>), we successfully generated adherent cell lines from single YFP<sup>+</sup> cells isolated from castrated and tamoxifen-treated <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice. Genotyping of the resulting lines led to identification of <italic>Ar</italic>-positive (non-recombined allele) and <italic>Ar</italic>-negative (recombined allele) lines, which we term APCA and ADCA (Ar-Positive CArn-derived and Ar-Deleted CArn-derived) lines. These cell lines could be propagated as adherent cells in the presence of Matrigel and DHT. Under these conditions, we found that the APCA (n = 2) and ADCA (n = 2) lines were morphologically indistinguishable (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). These cell lines were comprised of a mixture of cells expressing basal (CK5) or luminal (CK8) markers or both, as well as Foxa1, an epithelial marker that encodes a transcriptional partner of AR (<xref ref-type="bibr" rid="bib19">Gao et al., 2003</xref>; <xref ref-type="bibr" rid="bib23">He et al., 2010</xref>) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Furthermore, both the APCA and ADCA lines showed robust proliferation at similar levels, as demonstrated by Ki67 immunostaining, CellTiter-Glo assays, and colony formation in the presence or absence of DHT (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>).</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.28768.009</object-id><label>Figure 4.</label><caption><title>Properties of cell lines established from CARNs and AR-deleted CARNs.</title><p>(<bold>A</bold>) Morphology and marker expression of cell lines derived from single YFP<sup>+</sup> cells from castrated and tamoxifen-treated control <italic>Nkx3.1<sup>CreERT2/+</sup>; R26R-YFP/+</italic> mice and <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice. The APCA lines (top) and ADCA lines (bottom) show similar bright-field morphology, expression of YFP, Foxa1, and Ki67, as well as co-expression of CK8 and CK5, but differ in expression of AR. (<bold>B</bold>) APCA and ADCA cell lines display similar cell growth at days 1, 2, 4, and 6 after plating in the absence or presence of DHT, as assessed by CellTiter-Glo assay. Results shown are from a single experiment with five technical replicates and are representative of two biological replicates after normalization with day 0 luminescent signal. (<bold>C</bold>) Colony formation by APCA and ADCA cell lines in the absence or presence of DHT. Results are from a single experiment with three technical replicates and are representative of two biological replicates. (<bold>D</bold>) Renal grafts generated from tissue recombinants of 100,000 APCA or ADCA cells with rat urogenital mesenchyme, and analyzed at 12 weeks. Bottom row shows APCA grafts treated with tamoxifen for 4 days at 7 weeks of growth to induce <italic>Ar</italic> deletion (bottom); arrows indicate cells that did not undergo <italic>Ar</italic> deletion after tamoxifen treatment. Scale bars in <bold>A</bold>) and <bold>D</bold>) correspond to 50 μm.</p><p><supplementary-material id="fig4sdata1"><object-id pub-id-type="doi">10.7554/eLife.28768.011</object-id><label>Figure 4—source data 1.</label><caption><title>Epithelial cell lines established from mouse and human prostate tissue.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-28768-fig4-data1-v3.docx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-28768-fig4-v3"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.28768.010</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Establishment of novel human prostate epithelial cell lines.</title><p>(<bold>A</bold>) Flow-sorting strategy to eliminate EpCAM<sup>–</sup>E-cadherin<sup>–</sup> cells from dissociated benign human prostate epithelial cells obtained from radical prostatectomies. (<bold>B</bold>) Bright-field images of a human prostate epithelial cell line at passages 3 and 6. (<bold>C</bold>) HPE cells broadly express AR and both luminal (CK8) and basal (CK5) markers, and have more limited expression of PSA and Ki67. Scale bars in <bold>B</bold>) correspond to 100 μm, and in <bold>C</bold>) to 50 μm.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-28768-fig4-figsupp1-v3"/></fig></fig-group><p>To determine the relative efficiency of forming APCA and ADCA lines from AR<sup>+</sup> and AR<sup>–</sup> CARNs, respectively, we sorted 60 single YFP<sup>+</sup> cells from castrated and tamoxifen-treated <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice into individual wells of a 96-well plate. We found that six YFP<sup>+</sup> cells gave rise to adherent lines, with four of these corresponding to AR<sup>+</sup> lines that had failed to undergo Cre-mediated recombination of the conditional <italic>Ar</italic> allele, and two lines corresponding to AR<sup>–</sup> lines. After correcting for the 87.1% efficiency of recombination of the AR-floxed allele in vivo, these data indicate that the relative plating efficiency for the AR<sup>–</sup> CARNs compared to AR<sup>+</sup> CARNs is 7.4%, consistent with the decreased grafting efficiency of AR<sup>–</sup> CARNs.</p><p>Notably, we were also able to use this methodology to establish 14 primary human prostate epithelial cell lines from benign prostatectomy specimens at high efficiency. Similar to the mouse APCA cell lines, these HPE (Human Prostate Epithelial) cell lines are propagated as adherent cells in the presence of Matrigel and DHT. All these lines display similar marker phenotypes, expressing basal and luminal markers as well as AR and PSA, and are highly proliferative (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><p>To assess the ability of the APCA and ADCA cell lines to reconstitute prostate ducts, we performed tissue recombination assays by combining 1 × 10<sup>5</sup> cells with rat urogenital mesenchyme followed by renal grafting. We found that the APCA lines could generate prostate ducts (n = 10 grafts with two lines; 100% efficiency), some with evidence of secretions, whereas the ADCA lines (n = 6 grafts with one line; 67% efficiency) generated ducts that lacked prostate secretions (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Next, we tested the role of AR in this tissue reconstitution assay by treating the mice grafted with APCA cells (n = 12 grafts with two lines) with tamoxifen at 7 weeks after grafting in order to induce <italic>Ar</italic> deletion. We found that tamoxifen treatment resulted in grafts containing prostate ducts composed of a mixture of AR-positive and negative cells, but with a decreased efficiency of graft formation relative to the same APCA lines in the absence of tamoxifen (42% versus 100% efficiency) (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Taken together, these results show that AR deletion decreases the efficiency of prostate duct formation by CARN-derived cells, consistent with the results obtained using AR-deleted CARNs (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Notably, since ADCA cells do not display a growth disadvantage relative to APCA cells in culture, this difference in duct formation is likely to be due to a non-cell-autonomous effect mediated by the urogenital mesenchyme in grafts.</p><p>To examine the molecular basis for differences between the ADCA and APCA lines (n = 2 lines each), we performed RNA-sequencing followed by bioinformatic analyses. Based on the RNA expression profiling data, we constructed a differential expression signature comparing ADCA cells to APCA cells. Using the resulting ADCA signature to examine pathway enrichment by Gene Set Enrichment Analysis (GSEA) (<xref ref-type="bibr" rid="bib47">Subramanian et al., 2005</xref>), we found up-regulation of gene sets involved in DNA replication and repair pathways, as well as cell cycle and apoptosis (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), suggesting that cellular proliferation and survival are affected by AR deletion. We also compared the ADCA signature with a signature defined between expression profiles of AR-null and AR-positive mouse prostate luminal cells (<xref ref-type="bibr" rid="bib59">Xie et al., 2017</xref>) and found enrichment for up-regulated genes (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Next, we performed a cross-species comparison of the ADCA signature with a signature defined between profiles of human prostate luminal and basal epithelial cells (<xref ref-type="bibr" rid="bib64">Zhang et al., 2016b</xref>) and found that there was no significant enrichment in either tail (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), indicating that AR deletion does not drive APCA cells towards a specific lineage. Furthermore, we performed GSEA comparisons of the ADCA signature with several signatures obtained from analyses of human prostate cancer progression. In particular, we observed enrichment for up-regulated genes when compared to a signature of CRPC from Best and colleagues (<xref ref-type="bibr" rid="bib7">Best et al., 2005</xref>), as well as to a signature of metastatic CRPC from Stanbrough and colleagues (<xref ref-type="bibr" rid="bib46">Stanbrough et al., 2006</xref>) (<xref ref-type="fig" rid="fig5">Figure 5D,E</xref>). Moreover, we observed a strong enrichment when compared to a signature from Beltran and colleagues (<xref ref-type="bibr" rid="bib4">Beltran et al., 2016</xref>) defined between CRPC with neuroendocrine differentiation (CRPC-NE) and non-neuroendocrine CRPC (<xref ref-type="fig" rid="fig5">Figure 5F</xref>), consistent with our observation of pathway enrichment for gene sets corresponding to axon guidance and small-cell lung cancer (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.28768.012</object-id><label>Figure 5.</label><caption><title>Gene set enrichment analysis of the ADCA signature.</title><p>(<bold>A</bold>) Selected biological pathways that are enriched in the ADCA versus APCA signature. (<bold>B</bold>) GSEA plot showing enrichment in the positive tail for a signature of AR-null mouse prostate epithelial cells. (<bold>C</bold>) Cross-species GSEA showing lack of enrichment with a signature based on isolated human prostate basal and luminal epithelial populations. (<bold>D–F</bold>) Cross-species GSEA comparing the ADCA expression signature with three independent expression signatures based on tumor samples from human patients. NES: normalized enrichment score; p-value is calculated using 1000 gene permutations.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-28768-fig5-v3"/></fig><p>Finally, we tested the ability of AR-deleted CARNs to serve as a cell of origin for prostate cancer, based on the previous finding that prostate cancer can initiate from CARNs after specific deletion of <italic>Pten</italic> and androgen-mediated regeneration (<xref ref-type="bibr" rid="bib53">Wang et al., 2009</xref>). We used <italic>Nkx3.1<sup>CreERT2/+</sup>; Pten<sup>flox/flox</sup>; R26R-YFP/+</italic> controls (which we term NP-CARN) and <italic>Nkx3.1<sup>CreERT2/+</sup>; Pten<sup>flox/flox</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice (NPA-CARN) in an experimental paradigm involving castration, tamoxifen-treatment, and androgen-mediated regeneration for one month. We found that AR deletion resulted in a significant difference between the NP-CARN and NPA-CARN phenotypes, as the NP-CARN controls displayed high-grade prostatic intraepithelial neoplasia (PIN), whereas the NPA-CARN prostates showed a weak phenotype corresponding to diffuse hyperplasia with mild inflammation and increased apoptosis, (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). The NPA-CARN prostates contained YFP-positive cells that also expressed phospho-Akt (pAkt), indicating successful deletion of <italic>Pten,</italic> but these cells were only found as solitary or as small clusters, unlike the large clusters of YFP<sup>+</sup>pAkt<sup>+</sup> cells observed in the control NP prostates (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Furthermore, the NPA-CARN prostates displayed a decreased proliferative index relative to NP-CARN (2.7%, n = 3 vs. 9.2%, n = 3), as well as increased apoptosis (2.6%, n = 3 vs. 0.7%, n = 3) (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Taken together, findings indicate that AR is required for tumor initiation following <italic>Pten</italic> deletion in CARNs.</p><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.28768.013</object-id><label>Figure 6.</label><caption><title>Deletion of AR alters the ability of CARNs to serve as a cell of origin for prostate cancer.</title><p>(<bold>A</bold>) Prostate histology and marker expression in <italic>Nkx3.1<sup>CreERT2/+</sup>; Pten<sup>flox/flox</sup>; R26R-YFP/+</italic> (NP-CARN) and <italic>Nkx3.1<sup>CreERT2/+</sup>; Pten<sup>flox/flox</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> (NPA-CARN) mice that have been castrated and tamoxifen-treated, followed by androgen-mediated regeneration for 1 month. Shown are representative images for hematoxylin-eosin staining (H and E) and immunofluorescence for YFP, AR, phospho-Akt (pAkt), E-cadherin (Ecad), Ki67, and cleaved caspase-3 (CC3). Arrows indicate occurrence of cell death (YFP/AR in NPA-CARN), proliferation (Ecad/Ki67), and apoptosis (Ecad/CC3). (<bold>B</bold>) Quantitation of Ki67<sup>+</sup> and CC3<sup>+</sup>-positive cells in total Ecad<sup>+</sup> epithelial cells in NP-CARN and NPA-CARN prostates. Error bars represent one standard deviation; differences between groups are statistically significant as determined by independent t-test. (<bold>C</bold>) Prostate tumor histology and marker expression in <italic>Nkx3.1<sup>CreERT2/+</sup>; Pten<sup>flox/flox</sup>; Kras<sup>LSL-G12D/+</sup>; R26R-YFP/+</italic> (NPK-CARN) and <italic>Nkx3.1<sup>CreERT2/+</sup>; Pten<sup>flox/flox</sup>; Kras<sup>LSL-G12D/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> (NPKA-CARN) mice that have been castrated and tamoxifen-treated, followed by androgen-mediated regeneration for 1 month. Arrows indicate cells undergoing proliferation (Ecad/Ki67) and apoptosis (Ecad/CC3). (<bold>D</bold>) Quantitation of Ki67<sup>+</sup> and CC3<sup>+</sup>-positive cells in total Ecad<sup>+</sup> epithelial cells in NPK-CARN and NPKA-CARN prostates. Differences between groups are not statistically significant as determined by independent t-test (Ki67, p=0.724; CC3, p=0.507). (<bold>E</bold>) Focal neuroendocrine differentiation in NPKA-CARN tumors. Shown are H and E and immunohistochemical staining (IHC) of serial sections for Synaptophysin (Syn) and Aurora kinase A (Aurka), IHC for Foxa2 and Chromogranin A (ChrA), as well as immunofluorescence for YFP and Syn shown as an overlay and as individual channels; arrows indicate positive cells. (<bold>F</bold>) Quantitation of Syn<sup>+</sup> cells in total epithelial cells in NPK-CARN and NPKA-CARN tumors. Scale bars for H and E and IHC in <bold>A, C,</bold>) and <bold>E</bold>) correspond to 100 μm, and in other panels to 50 μm.</p><p><supplementary-material id="fig6sdata1"><object-id pub-id-type="doi">10.7554/eLife.28768.014</object-id><label>Figure 6—source data 1.</label><caption><title>Tumor phenotypes and marker quantitation.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-28768-fig6-data1-v3.docx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-28768-fig6-v3"/></fig><p>In contrast, AR deletion did not affect tumor initiation following combined deletion of <italic>Pten</italic> and activation of the oncogenic <italic>Kras<sup>G12D</sup></italic> allele. Using a similar protocol for castration, tamoxifen-treatment, and androgen-mediated regeneration, we compared the phenotypes of <italic>Nkx3.1<sup>CreERT2/+</sup>; Pten<sup>flox/flox</sup>; Kras<sup>LSL-G12D/+</sup>; R26R-YFP/+</italic> controls (NPK-CARN) and <italic>Nkx3.1<sup>CreERT2/+</sup>; Pten<sup>flox/flox</sup>; Kras<sup>LSL-G12D/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice (NPKA-CARN). In both genotypes, deletion of <italic>Pten</italic> and activation of oncogenic <italic>Kras</italic> resulted in formation of tumors with large clusters of YFP<sup>+</sup> cells that express pAkt and Ras (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Furthermore, both NPK-CARN and NPKA-CARN tumors displayed high proliferative indices (20%, n = 3 vs. 19%, n = 3) and low frequencies of apoptosis (0.9%, n = 3 vs. 0.8%, n = 3) (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Notably, we observed an important difference between the NPK-CARN and NPKA-CARN tumors, as all the NPKA-CARN tumors contained a low but variable percentage of synaptophysin-positive neuroendocrine cells among total epithelial cells (0.7%, n = 3), which were never observed in the NPK-CARN controls (0%, n = 3) (<xref ref-type="fig" rid="fig6">Figure 6E,F</xref>). We also observed rare cells in all three NPKA-CARN tumors that expressed other neuroendocrine markers such as Chromogranin A, Foxa2, and Aurora kinase A (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Since the synaptophysin-postive cells co-expressed YFP (<xref ref-type="fig" rid="fig6">Figure 6E</xref>), we conclude that transformed AR-negative CARNs can give rise to neuroendocrine cells.</p></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Taken together, our analyses have defined specific roles for AR in regulating the progenitor properties of CARNs, and indicate that the intrinsic castration-resistance of CARNs is independent of AR function. We find that targeted deletion of AR does not affect the percentage of CARNs, their luminal marker expression, or their ability to generate basal cells during androgen-mediated regeneration. However, there are fewer luminal progeny from AR-deleted CARNs during regeneration in vivo, and there is a decreased efficiency of prostate duct formation by both AR-deleted CARNs and ADCA cells in renal grafts. Thus, AR deletion in CARNs may primarily affect the proliferation and/or survival of their luminal progeny in vivo, although an effect on CARNs themselves cannot be excluded.</p><p>Interestingly, our results suggest potential roles of the stroma in modulating the proliferation of CARNs and/or their luminal progeny. Notably, BrdU incorporation assays reveal a proliferation defect of AR-deleted CARNs during later stages of regeneration but not during early regeneration. One possible explanation is that AR activity may cell-autonomously regulate the proliferation of luminal progeny of CARNs; alternatively, however, stromal remodeling during later stages of regeneration may alter non-cell autonomous signals that regulate luminal proliferation. Furthermore, since ADCA cells do not display a growth defect in culture, their decreased efficiency of prostate duct formation in grafts is likely due to a non-cell-autonomous inhibitory effect from the stroma.</p><p>Our study has also yielded interesting insights into differences between CARNs and other luminal epithelial cells. While this manuscript was in preparation, another study also investigated the requirements of AR in CARNs, and reported that AR-deleted CARNs completely failed to generate progeny during regeneration (<xref ref-type="bibr" rid="bib59">Xie et al., 2017</xref>). This apparent discrepancy may be partially explained by our observation that AR-deleted CARNs can still generate basal progeny, and by the failure of progeny from AR-deleted CARNs to proliferate at later stages of androgen-mediated regeneration. However, we concur that CARNs require AR function to generate viable luminal progeny, which is not the case for most luminal cells during homeostasis or regeneration (<xref ref-type="bibr" rid="bib59">Xie et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Zhang et al., 2016a</xref>). Furthermore, the decreased proliferation of AR-deleted CARNs during regeneration contrasts with the transient increase in luminal proliferation observed after inducible AR deletion in the adult prostate epithelium, which is also a non-cell-autonomous effect mediated by the stroma (<xref ref-type="bibr" rid="bib63">Zhang et al., 2016a</xref>). Together with our previous finding that CARNs display increased organoid formation efficiency relative to other luminal cells (<xref ref-type="bibr" rid="bib13">Chua et al., 2014</xref>), these findings support the identification of CARNs as a distinct luminal population with stem/progenitor properties, and highlight the complexity of AR functions in the epithelial and stromal compartments.</p><p>In addition, we note that Xie and colleagues reported that <italic>Pten</italic> deletion in CARNs resulted in tumor formation after regeneration (<xref ref-type="bibr" rid="bib59">Xie et al., 2017</xref>), unlike the absence of tumors that we observe in NPA-CARN mice. At present, the basis for this discrepancy remains unclear. Our finding that AR deletion results in failure of tumor formation following <italic>Pten</italic> inactivation could be due to differences between CARNs and bulk luminal cells and/or to differences due to <italic>Pten</italic> loss in the regressed versus hormonally intact prostate epithelium. In principle, these possibilities could potentially be distinguished using inducible Cre-drivers to delete <italic>Pten</italic> in bulk luminal cells in regressed versus hormonally intact mice.</p><p>Our findings on CARNs in mouse models may be of potential relevance for human prostate biology and cancer. Although CARNs are defined in the regressed prostate epithelium, and our in vivo studies involve manipulations performed after castration in mice, there is evidence that CARN-like cells exist in the human prostate from tissue-slice culture experiments (<xref ref-type="bibr" rid="bib65">Zhao et al., 2010</xref>), as well as from analyses of prostate tumors after androgen-deprivation (<xref ref-type="bibr" rid="bib20">Germann et al., 2012</xref>). However, it is less clear whether multipotent luminal progenitors can be identified in the context of the hormonally intact human prostate. Previous lineage-reconstruction studies using patterns of mitochondrial DNA mutations have indicated the existence of multipotent epithelial progenitors (<xref ref-type="bibr" rid="bib8">Blackwood et al., 2011</xref>; <xref ref-type="bibr" rid="bib18">Gaisa et al., 2011</xref>), and recent work has provided evidence for multipotent basal progenitors localized to the most proximal region of the prostate as well as more distally located unipotent luminal progenitors (<xref ref-type="bibr" rid="bib38">Moad et al., 2017</xref>). Notably, <italic>ex vivo</italic> studies of human prostate organoids have demonstrated the existence of bipotential luminal progenitors (<xref ref-type="bibr" rid="bib26">Karthaus et al., 2014</xref>). Thus, we believe that current data favor a general similarity of epithelial lineage relationships in the two species, suggesting that findings deduced from analyses of mice may be translatable to the human prostate.</p><p>The ability of CARNs to retain progenitor properties even in the absence of AR raises the possibility that CARNs represent a cell of origin for prostate cancers that are particularly susceptible to develop castration-resistance. Notably, under conditions of AR down-regulation, such as those that may occur during aging or inflammation, CARNs that lack tumor suppressors such as PTEN may represent a latent target for subsequent oncogenic events that can confer tumor growth, such as those activating the ERK MAP kinase pathway. Interestingly, our bioinformatic analyses of the ADCA cell line signature shows enrichment with castration-resistance signatures based on expression data from human prostate cancer patients (Best and Stanbrough signatures), consistent with increasing evidence supporting AR-independent mechanisms of castration-resistance (<xref ref-type="bibr" rid="bib6">Beltran et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Vlachostergios et al., 2017</xref>; <xref ref-type="bibr" rid="bib57">Watson et al., 2015</xref>). In addition, the observed enrichment with the Beltran CRPC-NE signature suggests a similarity in gene expression programs with advanced cancers that lack AR activity, as neuroendocrine differentiation in prostate tumors is associated with loss of AR expression (<xref ref-type="bibr" rid="bib5">Beltran et al., 2011</xref>). Notably, consistent with a role for AR loss in the emergence of neuroendocrine phenotypes, tumors in NPKA-CARN mice can display focal neuroendocrine differentiation, which has also been recently described in other mouse models of advanced prostate cancer (<xref ref-type="bibr" rid="bib27">Ku et al., 2017</xref>; <xref ref-type="bibr" rid="bib66">Zou et al., 2017</xref>).</p><p>In this regard, we note that the NP-CARN and NPK-CARN mice develop tumor phenotypes similar to those in NP and NPK mice, which have the same genotypes but whose tumors are induced by the <italic>Nkx3.1<sup>CreERT2</sup></italic> driver in hormonally intact adult prostate (<xref ref-type="bibr" rid="bib1">Aytes et al., 2013</xref>; <xref ref-type="bibr" rid="bib17">Floc'h et al., 2012</xref>). Interestingly, NP tumors are initially castration-sensitive (<xref ref-type="bibr" rid="bib17">Floc'h et al., 2012</xref>), consistent with the inability of NPA-CARN mice to develop tumors, whereas NPK tumors are castration-resistant (<xref ref-type="bibr" rid="bib1">Aytes et al., 2013</xref>), consistent with the phenotype of NPKA-CARN tumors. The molecular basis for this switch is currently unclear, but it is conceivable that it involves ETS family transcription factors, which are known to interact with AR to positively and negatively modulate its activity (<xref ref-type="bibr" rid="bib2">Baena et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Bose et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2013</xref>); interestingly, ETV4 is up-regulated in NPK tumors and may be involved in this switch (<xref ref-type="bibr" rid="bib1">Aytes et al., 2013</xref>). However, the focal neuroendocrine differentiation observed in NPKA-CARN tumors suggests that oncogenic transformation of AR-deleted CARNs can also facilitate transdifferentiation of luminal cells to neuroendocrine fates, as we have demonstrated for a <italic>Pten</italic> and <italic>Trp53</italic> mutant mouse model (NPp53) after anti-androgen treatment (<xref ref-type="bibr" rid="bib66">Zou et al., 2017</xref>).</p><p>Finally, since tumors initiated from CARNs following combined <italic>Pten</italic> deletion and <italic>Kras</italic> activation are at least partially independent of AR from their outset, it is conceivable that such tumors are intrinsically more resistant to second-generation anti-androgen therapies. Interestingly, recent studies have also identified distinct castration-resistant progenitors that express Bmi1 (CARBs) that are cells of origin for prostate cancer (<xref ref-type="bibr" rid="bib62">Yoo et al., 2016</xref>). The development of targeted therapies directed at molecular features of CARNs and/or other castration-resistant luminal cells may therefore be relevant for successful combination with anti-androgen therapies.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type (species) <break/>or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Strain (<italic>M. musculus</italic>)</td><td valign="top">NOG</td><td valign="top">PMID: 15879151</td><td valign="top">NOD.Cg-<italic>Prkdc<sup>scid</sup></italic> <break/><italic>Il2rg<sup>tm1Sug</sup></italic>/JicTac</td><td valign="top">Taconic (Hudson, NY)</td></tr><tr><td valign="top">Strain (<italic>M. musculus</italic>)</td><td valign="top"><italic>Nkx3.1<sup>CreERT2</sup></italic></td><td valign="top">PMID: 19741607</td><td valign="top"><italic>Nkx3-1<sup>tm4(CreERT2)Mms</sup></italic></td><td valign="top">established by Shen lab</td></tr><tr><td valign="top">Strain (<italic>M. musculus</italic>)</td><td valign="top"><italic>Pten<sup>flox</sup></italic></td><td valign="top">PMID: 11691952</td><td valign="top">C;129S4-<italic>Pten<sup>tm1Hwu</sup></italic>/J</td><td valign="top">JAX #004597 (Bar Harbor, ME)</td></tr><tr><td valign="top">Strain (<italic>M. musculus</italic>)</td><td valign="top"><italic>Kras<sup>LSL-G12D</sup></italic></td><td valign="top">PMID: 11751630</td><td valign="top">B6.129-<italic>Kras<sup>tm4Tyj</sup></italic>/Nci</td><td valign="top">MMHCC #01XJ6</td></tr><tr><td valign="top">Strain (<italic>M. musculus</italic>)</td><td valign="top"><italic>AR<sup>flox</sup></italic></td><td valign="top">PMID: 14745012</td><td valign="top">B6N.129-<italic>Ar<sup>tm1Verh</sup></italic>/Cnrm</td><td valign="top">EMMA #02579</td></tr><tr><td valign="top">Strain (<italic>M. musculus</italic>)</td><td valign="top"><italic>R26R-YFP</italic></td><td valign="top">PMID: 11299042</td><td valign="top">B6.129 × 1-<italic>Gt(ROSA)</italic> <break/><italic>26Sor<sup>tm1(EYFP)Cos</sup></italic>/J</td><td valign="top">JAX #006148</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HPE-1</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 23 tissue, sorted for EpCAM<sup>+</sup>Ecad<sup>+</sup> cells</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-2</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 23 tissue, sorted for EpCAM<sup>+</sup>Ecad<sup>+</sup> cells</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-3</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 24 tissue, sorted for EpCAM<sup>+</sup>Ecad<sup>+</sup> cells</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-4</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 25 tissue</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-5</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 25 tissue, sorted for EpCAM<sup>+</sup>Ecad<sup>+</sup> cells</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-6</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 25 tissue, sorted for EpCAM<sup>+</sup>Ecad<sup>+</sup>Ngfr<sup>+</sup> cells</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-7</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 25 tissue, sorted for EpCAM<sup>+</sup>Ecad<sup>+</sup>Cd24<sup>+</sup> cells</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-8</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 26 tissue</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-9</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 26 tissue, sorted for EpCAM<sup>+</sup>Ecad<sup>+</sup> cells</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-10</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 26 tissue, sorted for EpCAM<sup>+</sup>Ecad<sup>+</sup>Cd24<sup>+</sup> cells</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-11</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 26 tissue, sorted for EpCAM<sup>+</sup>Ecad<sup>+</sup>Agr2<sup>+</sup> cells</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-12</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 27 tissue</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-13</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 27 tissue; sorted for EpCAM<sup>+</sup>Ecad<sup>+</sup>cells</td></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">HPE-14</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from radical prostatectomy 27 tissue, sorted for EpCAM<sup>+</sup>Ecad<sup>+</sup>Cd24<sup>+</sup> cells</td></tr><tr><td valign="top">Cell line (<italic>M. musculus</italic>)</td><td valign="top">ADCA-1</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from single YFP<sup>+</sup> cell isolated from castrated and tamoxifen-treated <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R262R-YFP/+</italic> mouse with deleted<italic>Ar</italic> (recombined) allele</td></tr><tr><td valign="top">Cell line (<italic>M. musculus</italic>)</td><td valign="top">ADCA-2</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from single YFP<sup>+</sup> cell isolated from castrated and tamoxifen-treated <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R262R-YFP/+</italic> mouse with deleted<italic>Ar</italic> (recombined) allele</td></tr><tr><td valign="top">Cell line (<italic>M. musculus</italic>)</td><td valign="top">APCA-1</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from single YFP<sup>+</sup> cell isolated from castrated and tamoxifen-treated <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R262R-YFP/+</italic> mouse with intact <italic>Ar</italic> (non-recombined) allele</td></tr><tr><td valign="top">Cell line (<italic>M. musculus</italic>)</td><td valign="top">APCA-2</td><td valign="top">this work</td><td valign="top"/><td valign="top">Adherent cell line established from single YFP<sup>+</sup> cell isolated from castrated and tamoxifen-treated <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R262R-YFP/+</italic> mouse with intact <italic>Ar</italic> (non-recombined) allele</td></tr><tr><td valign="top">Antibody</td><td valign="top">Androgen receptor (AR)</td><td valign="top">Sigma (St. Louis, MO)</td><td valign="top">A9853</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Cytokeratin 8 (CK8)</td><td valign="top">Developmental Studies Hybridoma Bank (Iowa City, IA)</td><td valign="top">TROMA-1</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Cytokeratin 18 (CK18)</td><td valign="top">Abcam <break/>(Cambridge, MA)</td><td valign="top">ab668</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Cytokeratin 5 (CK5)</td><td valign="top">Covance <break/>(San Diego, CA)</td><td valign="top">SIG3475</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Cytokeratin 5 (CK5)</td><td valign="top">Covance</td><td valign="top">PRB-160P</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">p63</td><td valign="top">Santa Cruz <break/>(Dallas, TX)</td><td valign="top">sc-8431</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">GFP</td><td valign="top">Abcam</td><td valign="top">ab13970</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">GFP</td><td valign="top">Roche <break/>(St. Louis, MO)</td><td valign="top">11814460001</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">BrdU</td><td valign="top">AbD Serotec MCA <break/>(Hercules, CA)</td><td valign="top">2060</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Foxa1</td><td valign="top">Abcam</td><td valign="top">ab55178</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Ki67</td><td valign="top">eBiosciences <break/>(San Diego, CA)</td><td valign="top">14–5698, clone SolA15</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Cleaved-caspase-3 (CC3)</td><td valign="top">BD Pharmingen <break/>(San Jose, CA)</td><td valign="top">559565</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Prostate specific antigen (PSA)</td><td valign="top">Dako <break/>(Santa Clara, CA)</td><td valign="top">M0750, clone ER-PR8</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Kras</td><td valign="top">Abcam</td><td valign="top">ab84573</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Synaptophysin (Syn)</td><td valign="top">BD Transduction <break/>Laboratories <break/>(San Jose, CA)</td><td valign="top">611880</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Aurora A (Aurka)</td><td valign="top">Abcam</td><td valign="top">ab13824</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Chromogranin A (ChrA)</td><td valign="top">Abcam</td><td valign="top">ab15160</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Foxa2</td><td valign="top">Abnova (Taiwan)</td><td valign="top">H00003170-M12</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">AMACR</td><td valign="top">Zeta Corp <break/>(Arcadia, CA)</td><td valign="top">Z2001</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">EpCAM</td><td valign="top">BioLegend</td><td valign="top">118214</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">E-cadherin</td><td valign="top">eBiosciences</td><td valign="top">46-3249-82</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Nerve growth factor <break/>receptor (Ngfr)</td><td valign="top">BioLegend</td><td valign="top">345108</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Cd24</td><td valign="top">BioLegend</td><td valign="top">311008</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Anterior gradient 2 (Agr2)</td><td valign="top">Abcam</td><td valign="top">ab1139894</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">EpCAM</td><td valign="top">BioLegend</td><td valign="top">324208</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Nkx3.1</italic> wild-type primers</td><td valign="top">PMID: 19741607</td><td valign="top">DOI 10.1038/nature08361</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Nkx3.1<sup>CreERT2</sup></italic> primers</td><td valign="top">PMID: 19741607</td><td valign="top">DOI 10.1038/nature08361</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>CreER<sup>T2</sup></italic> primers</td><td valign="top">PMID: 19741607</td><td valign="top">DOI 10.1038/nature08361</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>R262R-YFP</italic> primers</td><td valign="top">PMID: 11299042</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Pten<sup>flox</sup></italic> primers</td><td valign="top">PMID: 11691952</td><td valign="top">DOI: 10.1126/science.1065518</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Pten</italic> wild-type primers</td><td valign="top">PMID: 11691952</td><td valign="top">DOI: 10.1126/science.1065518</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Kras<sup>LSL-G12D</sup></italic> primers</td><td valign="top">PMID: 11751630</td><td valign="top">DOI:10.1101/gad.943001</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Kras</italic> wild-type primers</td><td valign="top">PMID: 11751630</td><td valign="top">DOI:10.1101/gad.943001</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Ar<sup>flox</sup></italic> primers</td><td valign="top">PMID: 14676301</td><td valign="top">DOI: 10.1084/jem.20031233</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Ar</italic> wild-type primers</td><td valign="top">PMID: 14676301</td><td valign="top">DOI: 10.1084/jem.20031233</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Ar<sup>flox</sup></italic> (recombined) primers</td><td valign="top">PMID: 14676301</td><td valign="top">DOI: 10.1084/jem.20031233</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Ar<sup>flox</sup></italic> (not recombined) primers</td><td valign="top">PMID: 14676301</td><td valign="top">DOI: 10.1084/jem.20031233</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Tyramide amplification</td><td valign="top">ThermoFisher Scientific <break/>(Waltham, MA)</td><td valign="top">T20922</td><td valign="top"/></tr><tr><td valign="top">Ccommercial assay or kit</td><td valign="top">Tyramide amplification</td><td valign="top">ThermoFisher Scientific</td><td valign="top">T30953</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Tyramide amplification</td><td valign="top">ThermoFisher Scientific</td><td valign="top">T30954</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Tyramide amplification</td><td valign="top">ThermoFisher Scientific</td><td valign="top">T20926</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Tyramide amplification</td><td valign="top">ThermoFisher Scientific</td><td valign="top">T20912</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">ABC Elite</td><td valign="top">Vector Labs <break/>(Burlingame, CA)</td><td valign="top">pk6101</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Citrate-based antigen <break/>unmasking solution</td><td valign="top">Vector Labs</td><td valign="top">H3300</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Tris-based antigen <break/>unmasking solution</td><td valign="top">Vector Labs</td><td valign="top">H3301</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">NovaRED</td><td valign="top">Vector Labs</td><td valign="top">SK3800</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">CellTiter-Glo 3D</td><td valign="top">Promega <break/>(Madison, Wi)</td><td valign="top">G9681</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">MagMAX−96forMicroarrays <break/>Total RNA Isolation Kit</td><td valign="top">Ambion <break/>(Waltham, MA)</td><td valign="top">Am1839</td><td valign="top">Used the ‘no spin’ protocol for RNA purification</td></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">TruSeq Stranded mRNA <break/>library prep kit</td><td valign="top">Illumina <break/>(San Diego, CA)</td><td valign="top">20020595</td><td valign="top">Library preparation was performed by the Columbia Genome Center using Illumina kits</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Tissue Tek OCT compound</td><td valign="top">VWR Scientific <break/>(Radnor, PA)</td><td valign="top">25608–930</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Glutamax</td><td valign="top">Invitrogen <break/>(Waltham, MA)</td><td valign="top">35050061</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Tamoxifen; TM</td><td valign="top">Sigma</td><td valign="top">T5648-5G</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Gentamicin</td><td valign="top">Invitrogen</td><td valign="top">15750–060</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Collagenase/hyaluronidase</td><td valign="top">STEMCELL Technologies <break/>(Cambridge, MA)</td><td valign="top">07912</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Modified Hank's Balanced <break/>Salt Solution; HBSS</td><td valign="top">STEMCELL Technologies</td><td valign="top">37150</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Dnase I</td><td valign="top">STEMCELL Technologies</td><td valign="top">07900</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Y-27632 ROCK inhibitor</td><td valign="top">STEMCELL Technologies</td><td valign="top">72307</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">10x Earle's Balanced <break/>Salt Solution</td><td valign="top">ThermoFisher <break/>Scientific</td><td valign="top">14155063</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Hepatocyte medium supplemented withepidermal growth factor (EGF)</td><td valign="top">Corning <break/>(Corning, NY)</td><td valign="top">355056</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Matrigel</td><td valign="top">ThermoFisher Scientific</td><td valign="top">354234</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">0.25% trypsin-EDTA</td><td valign="top">STEMCELL Technologies</td><td valign="top">07901</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">FBS</td><td valign="top">ThermoFisher Scientific</td><td valign="top">12676029</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DMEM/F12</td><td valign="top">ThermoFisher Scientific</td><td valign="top">11320033</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">BrdU</td><td valign="top">Sigma</td><td valign="top">B5002</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Dispase</td><td valign="top">STEMCELL Technologies</td><td valign="top">07913</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Dihydrotestosterone; DHT</td><td valign="top">Sigma</td><td valign="top">A8380</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Real time analysis; RTA</td><td valign="top">Illumina</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://support.illumina.com/sequencing/sequencing_software/real-time_analysis_rta.html">https://support.illumina.com/sequencing/sequencing_software/real-time_analysis_rta.html</ext-link></td><td valign="top">Base calling using this software was performed by the Columbia Genome Center</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">bcl2fastq2</td><td valign="top">Illumina</td><td valign="top">Ilumina: version 2.17</td><td valign="top">The sequencing data was trimmed and converted to fastq format by the Columbia Genome Center</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Spliced Transcripts Alignment <break/>to a Reference (STAR)</td><td valign="top">PMID: 23104886</td><td valign="top">Github: version 2.5.2b</td><td valign="top">Sequencing reads mapping to mouse genome (USCS/mm10) was performed by the Columbia Genome Center</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">FeatureCounts</td><td valign="top">PMID: 24227677</td><td valign="top">subread.sourceforge.net <break/>version: v1.5.0-p3</td><td valign="top">Sequencing reads mapping to mouse genome (USCS/mm10) was performed by the Columbia Genome Center</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">R-studio 0.99.902, R v3.3.0</td><td valign="top">The R Foundation for <break/>Statistical Computing, <break/>ISBN 3-900051-07-0</td><td valign="top">v3.3.0</td><td valign="top">R language for statistical computing was used for data analysis and visualization</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">homoloGene</td><td valign="top">NCBI</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Gene Set Enrichment Analysis</td><td valign="top">PMID: 16199517</td><td valign="top">DOI 10.1073/pnas.0506580102</td><td valign="top">GSEA was used to compares differential gene expression signatures</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Statistical Package for the Social Sciences; SPSS, Kolmogorov-Smirnov test, Arcsine transformation, Welch t-test, Fisher's Exact Test</td><td valign="top">IBM SPSS Statistics</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Histological grading of <break/>mouse prostate phenotypes</td><td valign="top">PMID: 12163397</td><td valign="top">DOI 10.1016/S0002-9440 <break/>(10)64228-9</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Mini-osmotic pump</td><td valign="top">Alzet (Cupertino, CA)</td><td valign="top">0000298</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">40 µm cell strainer</td><td valign="top">Falcon (Corning, NY)</td><td valign="top">Fisher Scientific 352340</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">96-well Primaria plate</td><td valign="top">Corning</td><td valign="top">Fisher Scientific 353872</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">6-well Primaria plate</td><td valign="top">Corning</td><td valign="top">Fisher Scientific 353846</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">96-well CELLSTAR plate</td><td valign="top">Greiner Bio-One <break/>(Monroe, NC)</td><td valign="top">655090</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Lab-Tek Chamber Slide</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">154534</td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mouse strains and genotyping</title><p>The <italic>Nkx3.1<sup>CreERT2</sup></italic> driver <italic>(Nkx3-1<sup>tm4(cre/ERT2)Mms</sup>)</italic> has been previously described (<xref ref-type="bibr" rid="bib53">Wang et al., 2009</xref>). Mice carrying the <italic>R26R-YFP</italic> (<italic>B6.129 × 1-Gt(ROSA)26Sor<sup>tm1(EYFP)Cos</sup>/J</italic>) reporter (<xref ref-type="bibr" rid="bib45">Srinivas et al., 2001</xref>) were obtained from the Jackson Laboratory Induced Mutant Resource. Mice carrying the conditional <italic>Pten<sup>flox</sup></italic> (B6.129S4-<italic>Pten<sup>tm1Hwu</sup>/J</italic>) allele (<xref ref-type="bibr" rid="bib33">Lesche et al., 2002</xref>) and the inducible <italic>Kras<sup>lsl-G12D</sup></italic> (B6.129-<italic>Kras<sup>tm4Tyj</sup>/Nci</italic>) allele (<xref ref-type="bibr" rid="bib25">Jackson et al., 2001</xref>) were obtained from the National Cancer Institute Mouse Models of Human Cancer Consortium Repository. Mice with the conditional <italic>Ar<sup>flox</sup></italic> (<italic>B6N.129-Ar<sup>tm1Verh</sup>/Cnrm</italic>) allele (<xref ref-type="bibr" rid="bib15">De Gendt et al., 2004</xref>) was obtained from the European Mouse Mutant Archive. Animals were maintained on a congenic C57BL/6N background. Genotyping was performed using the primers listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1A</xref>. Primer sequences used for genotyping of <italic>Ar</italic> alleles were previously described (<xref ref-type="bibr" rid="bib61">Yeh et al., 2003</xref>).</p></sec><sec id="s4-2"><title>Mouse procedures</title><p>For lineage-marking and simultaneous deletion of AR in CARNs, <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> males were castrated at 8 weeks of age and allowed to regress for 4 weeks, followed by administration of tamoxifen (Sigma; 9 mg/40 g body weight in corn oil) by daily oral gavage for four consecutive days, and a chase period of 4 weeks. Administration of testosterone for prostate regeneration (Sigma; 25 mg/ml in 100% ethanol and diluted in PEG-400 to a final concentration of 7.5 mg/ml) was performed by subcutaneous implantation of mini-osmotic pumps (Alzet) that release testosterone solution at a rate of 1.875 μg/hr, which yields physiological levels of serum testosterone (<xref ref-type="bibr" rid="bib3">Banach-Petrosky et al., 2007</xref>). For BrdU incorporation experiments, BrdU (Sigma; 100 mg/kg) was administered by intraperitoneal injection twice daily for 4 consecutive days, either from days 1 through 4 or from days 11 through 14 during androgen-mediated regeneration.</p><p>For cell of origin experiments, <italic>Nkx3.1<sup>CreERT2/+</sup>; Pten<sup>flox/flox</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> and <italic>Nkx3.1<sup>CreERT2/+</sup>; Pten<sup>flox/flox</sup>; Kras<sup>LSL-G12D/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice as well as corresponding controls were castrated at 8 to 12 weeks of age. One month later, mice were administered tamoxifen, with a chase period of 3 months, followed by androgen-mediated regeneration for 1 month; mice were then euthanized for analysis. All animal experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee at Columbia University Medical Center.</p></sec><sec id="s4-3"><title>Benign human prostate specimens</title><p>Radical prostatectomy samples were obtained from consented patients under the auspices of an Institutional Review Board approved protocol at Columbia University Medical Center. Tissue from benign prostate regions was dissected and transported to the laboratory in DMEM/F12 (Gibco) supplemented with 5% FBS. Benign pathology was first determined by H and E-staining of snap-frozen sections, and subsequently confirmed by immunostaining of paraffin sections for p63 and AMACR.</p></sec><sec id="s4-4"><title>Tissue acquisition, dissociation and isolation of prostate epithelial cells</title><p>Tissue dissociation and isolation were performed as previously described (<xref ref-type="bibr" rid="bib13">Chua et al., 2014</xref>). In brief, mouse prostate tissue from all lobes was dissected in cold phosphate buffered saline (PBS) and minced with scissors. For human prostate specimens, tissue was cut into small pieces with scalpels, washed with PBS with 4 mg/ml Gentamicin (Gibco), and then minced with scissors. Both mouse and human prostate tissues were then incubated in DMEM/F12 (Gibco) supplemented with 5% FBS and 1:10 dilution of collagenase/hyaluronidase (STEMCELL Technologies) at 37°C for 3 hr. Dissociated tissues were spun at 350 g for 5 min, and resuspended in ice-cold 0.25% trypsin-EDTA (STEMCELL Technologies), followed by incubation at 4°C for 1 hr. Trypsinization was stopped by addition of Modified Hank’s Balanced Salt Solution (HBSS) (STEMCELL Technologies) supplemented with 2% FBS. After centrifugation at 350 g, pelleted cells were resuspended with pre-warmed 5 mg/ml dispase (STEMCELL Technologies) supplemented with 1:10 dilution of 1 mg/ml DNase I (STEMCELL Technologies), triturated vigorously for 1 to 2 min, and diluted by addition of HBSS/2% FBS. Finally, the cell suspension was passed through a 40 μm cell strainer (Falcon).</p></sec><sec id="s4-5"><title>Flow cytometry</title><p>For flow sorting of mouse prostate epithelial cells, cell suspensions were stained on ice for 25 min with fluorescent-tagged EpCAM (BioLegend #118214) antibody. For isolation of human prostate epithelial cells, we used fluorescent-tagged EpCAM (BioLegend #324208, specific for human) and E-cadherin (eBioscience #46-3249-82) antibodies. The stained cells were spun, and cell pellets washed with HBSS/2% FBS, followed by resuspension in HBSS/2% FBS with 10 µM Y-27632 (ROCK inhibitor; STEMCELL Technologies) and a 1:1000 dilution of 0.5 mg/ml DAPI to exclude dead cells. Both side-scatter pulse width (SSC-W) vs. area (SSC-A) and forward side-scatter pulse area (FSC-A) vs. heights (FSC-H) were used to isolate single dissociated cells.</p></sec><sec id="s4-6"><title>Adherent culture for mouse and human prostate epithelial cells</title><p>To establish cell lines from lineage-marked CARNs as well as benign prostate epithelial cells, we performed adherent culture in our prostate organoid medium (<xref ref-type="bibr" rid="bib13">Chua et al., 2014</xref>), consisting of hepatocyte medium supplemented with 10 ng/ml epidermal growth factor (EGF) (Corning), 10 μM Y-27632 (STEMCELL Technologies), 1x glutamax (Gibco), 5% Matrigel (Corning), 5% charcoal-stripped FBS (Gibco) heat-inactivated at 55°C for 1 hr, and supplemented with either 100 nM or 1 nM DHT (Sigma) for mouse and human cells, respectively. To derive APCA and ADCA lines, single YFP<sup>+</sup> cells from castrated and tamoxifen-treated <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice were flow-sorted directly into 96-well Primaria plates (Corning), and were monitored daily to assess colony formation. Successful colonies were expanded and genotyped to assess the status of the <italic>Ar<sup>flox</sup></italic> allele. For derivation of lines from benign human prostate epithelium, cells expressing either EpCAM and/or E-cadherin were plated into six-well Primaria plates at a density of 100,000 cells/well.</p><p>Passaging of adherent cultures was performed by removal of accumulated Matrigel on surface of the cells by gentle washing. The cells were washed with cold PBS, treated with 0.25% trypsin for 5 min at 37°C, and mechanically dissociated. Medium was changed every 4 days. Adherent cells were frozen in media consisting of 80% FBS, 10% complete medium, and 10% DMSO. Each APCA and ADCA line has been propagated continuously for at least eight passages.</p></sec><sec id="s4-7"><title>Cell culture assays</title><p>To assess cell viability, APCA and ADCA lines were plated in 96-well Primaria plates at a density of 1000 cells/well in the presence or absence of DHT. Cell viability was assayed at days 1, 2, 4 and 6 after plating using CellTiter-Glo 3D (Promega), with five technical replicates for each time point. In brief, CellTiter-Glo 3D reagent was thawed at 4°C and brought to room temperature prior to use. 100 μl of the reagent was added into each well containing 100 μl of medium. After shaking for 5–10 min, the mixture was then transferred to a 96-well CELLSTAR plate (Greiner), followed by incubation at room temperature for 10 min prior to measurement using a luminometer plate reader.</p><p>To assess colony formation, APCA and ADCA lines were plated in six-well Primaria plates at a density of 500 cells/well and grown for 9 days. three technical replicates were performed for each line in the presence or absence of DHT. At day 10 after plating, wells were washed with PBS and fixed with 100% methanol for 5 min. The wells were then washed with PBS for three times before staining with filtered 0.1% crystal violet solution. After drying the plates, colonies were counted, with a colony defined as a cell cluster containing at least 50 cells.</p></sec><sec id="s4-8"><title>Tissue recombination and renal grafting</title><p>For tissue recombination, 10 YFP<sup>+</sup> cells from castrated and tamoxifen-treated <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26R-YFP/+</italic> mice or control <italic>Nkx3.1<sup>CreERT2/+</sup>; R26R-YFP/+</italic> mice were combined with 250,000 dissociated rat urogenital mesenchyme cells from embryonic day 18.5 embryos, and resuspended in 15 μl of 9:1 collagen:setting buffer solution (10x Earle’s Balanced Salt Solution (Life Technologies), 0.2 M NaHCO<sub>3</sub>, and 50 mM NaOH). The recombinants were cultured overnight in DMEM with 10% FBS and 100 nM DHT, followed by grafting under the kidney capsules of male NOD.Cg-<italic>Prkdc<sup>scid</sup> Il2rg<sup>tm1Sug</sup></italic>/JicTac (NOG) mice (Taconic). Renal grafts were harvested for analysis at 7–12 weeks after grafting. For the experiment involving APCA and ADCA lines, 100,000 cells were recombined with 250,000 rat urogenital mesenchyme cells, followed by grafting. At 6 weeks after grafting, some mice implanted with APCA cells were treated with tamoxifen to induce <italic>Ar</italic> deletion.</p><p>Grafts were harvested for analysis after 12 weeks of growth and analyzed in paraffin sections for the presence of ducts expressing YFP. (Note that ducts can also be formed by YFP<sup>–</sup>cells that are derived from contaminating rat urogenital epithelium due to incomplete separation from the urogenital mesenchyme.) Graft efficiency was calculated on the basis of the presence of YFP<sup>+</sup> ducts in the grafts using control CARNs and on the presence of YFP<sup>+</sup>AR<sup>–</sup> ducts in the grafts using AR-deleted CARNs.</p></sec><sec id="s4-9"><title>Histology and immunostaining</title><p>For cryosections, tissues were fixed in 4% paraformaldehyde in PBS at 4°C overnight, placed in 30% sucrose in PBS overnight, and transferred to 1:1 30% sucrose in PBS and OCT (Tissue-Tek) solution for at least 4 hr prior to embedding in OCT. For paraffin sections, tissues were fixed in 10% formalin for 1 to 2 days, depending on size of tissue, prior to processing and embedding. Hematoxylin-eosin staining was performed using standard protocols. For immunostaining, sections underwent antigen-retrieval by heating in citrate acid-based or tris-based antigen unmasking solution (Vector Labs) for 45 min. Primary antibodies were applied to sections and incubated at 4°C overnight in a humidified chamber. Alexa Fluors (Life Technologies) were used as secondary antibodies. In some cases, tyramide amplification (Life Technologies) or ABC Elite (Vector Labs) kits together with HRP-conjugated or biotinylated secondary antibodies and NovaRed kit were used for signal detection. For immunofluorescent staining of cells, 5000 adherent cells/well were seeded on a eight-well Lab-Tek Chamber Slide (Nunc), grown for 4–8 days, and fixed with 4% paraformaldehyde for 10 min. After washing the slides with 3 changes of PBS, immunostaining was performed as above without antigen retrieval. Details of antibodies used are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1B</xref>.</p><p>Histological grading of mouse prostate phenotypes was performed according to (<xref ref-type="bibr" rid="bib41">Park et al., 2002</xref>). For lineage-tracing experiments, quantitation of marker staining was performed by manual counting of cells from confocal images taken with a 40x objective.</p></sec><sec id="s4-10"><title>RNA sequencing and bioinformatic analysis</title><p>For RNA preparation, APCA and ADCA cell lines at passage 5 or 6 were grown to approximately 70–80% confluency in Primaria 6-well plates in the presence of DHT, and lysed in Trizol. Total RNA extraction was performed using the ‘No Spin’ method of the MagMAX-96 for Microarrays kit (Ambion). Library preparation and RNA sequencing was performed by the Columbia Genome Center using their standard pipeline. In brief, mRNA was enriched by poly-A pull-down, and library preparation was performed using an Illumina TruSeq RNA prep kit. Libraries were pooled and sequenced using an Illumina HiSeq2500 instrument, yielding approximately 30 million single-ended 100 bp reads per sample. RTA (Illumina) was used for base calling and bcl2fastq2 (version 2.17) for conversion of BCL to fastq format, coupled with adaptor trimming. Reads were mapped to the mouse genome (UCSC/mm10) using STAR (2.5.2b) and FeatureCounts (v1.5.0-p3).</p><p>RNA-seq data raw counts were normalized and the variance was stabilized using DESeq2 package (Bioconductor) in R-studio 0.99.902, R v3.3.0 (The R Foundation for Statistical Computing, ISBN 3-900051-07-0). Differential gene expression signatures were defined as a list of genes ranked by their differential expression between any two phenotypes of interest (e.g. APCA versus ADCA lines; CRPC-NE versus CRPC, etc.), estimated using a two-sample two-tailed Welch t-test (for n ≥ 3) or fold-change (for n &lt; 3). For comparison of a mouse gene signature with a human gene signature, mouse genes were mapped to their corresponding human orthologs based on the homoloGene database (NCBI). Signatures were compared using Gene Set Enrichment Analysis (GSEA) (<xref ref-type="bibr" rid="bib47">Subramanian et al., 2005</xref>), with the significance of enrichment estimated using 1000 gene permutations. Pathway enrichment analysis was performed using the C2 database, which includes pathways from REACTOME (<xref ref-type="bibr" rid="bib16">Fabregat et al., 2016</xref>), KEGG (<xref ref-type="bibr" rid="bib40">Ogata et al., 1999</xref>), and BioCarta (<ext-link ext-link-type="uri" xlink:href="http://www.biocarta.com/genes/allpathways.asp">http://www.biocarta.com/genes/allpathways.asp</ext-link>). Expression data are deposited in the Gene Expression Omnibus database under GSE99233.</p></sec><sec id="s4-11"><title>Statistical analyses</title><p>Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS). Data distribution was assessed by the Kolmogorov-Smirnov test. Arcsine transformation was performed on data with non-normal distribution. Two-sample two-tail Welch t-test or Fisher’s Exact Test was performed for comparison between two independent groups as appropriate. No statistical methods were used to pre-determine sample size, and experiments were not randomized; investigators were not blinded to allocation during experiments and outcome assessment.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Robert Cardiff for advice on histology and Cory Abate-Shen, Laura Crowley, Maximilian Marhold, Maho Shibata, and Roxanne Toivanen for insightful discussions and comments on the manuscript. Our studies used the CCTI Flow Cytometry Core (supported in part by the Office of the Director, National Institutes of Health under awards S10RR027050), and the HICCC Molecular Pathology Shared Resource. This work was supported by post-doctoral fellowships from the DOD Prostate Cancer Research Program (CWC, BIL), by a Rutgers SHP Dean’s Research Intramural grant (AM), and by grants from the Prostate Cancer Foundation (MMS) and the National Institutes of Health (MMS).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Funding acquisition, Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Supervision, Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Resources, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Data curation, Software, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing—original draft, Project administration</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Radical prostatectomy samples were obtained from consented patients under the auspices of an Institutional Review Board approved protocol AAAC4997 at Columbia University Medical Center.</p></fn><fn fn-type="other"><p>Animal experimentation: All animal experiments were performed under protocol AAAR9408, which was approved by the Institutional Animal Care and Use Committee at Columbia University Medical Center.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.28768.015</object-id><label>Supplementary file 1.</label><caption><title>Primers and antibodies used in this study.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-28768-supp1-v3.docx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.28768.016</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-28768-transrepform-v3.docx"/></supplementary-material><sec id="s7" sec-type="datasets"><title>Major datasets</title><p>The following dataset was generated:</p><p><related-object content-type="generated-dataset" id="dataset1" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99233" source-id-type="uri"><collab collab-type="author">Chua</collab><collab collab-type="author">CW</collab><collab collab-type="author">Li BI</collab><collab collab-type="author">Mitrofanova</collab><collab collab-type="author">A</collab><collab collab-type="author">Shen MM</collab><year>2017</year><source>Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation (APCA and ADCA lines RNASeq)</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99233">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99233</ext-link><comment>GSE99233</comment></related-object></p><p>The following previously published datasets were used:</p><p><related-object content-type="generated-dataset" id="dataset2" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2443" source-id-type="uri"><collab collab-type="author">Best CJ</collab><collab collab-type="author">Gillespie JW</collab><collab collab-type="author">Yi Y</collab><collab collab-type="author">Chandramouli GV</collab><collab collab-type="author">Perlmutter MA</collab><collab collab-type="author">Gathright Y</collab><collab collab-type="author">Erickson HS</collab><collab collab-type="author">Georgevich L</collab><collab collab-type="author">Tangrea MA</collab><collab collab-type="author">Duray PH</collab><collab collab-type="author">González S</collab><collab collab-type="author">Velasco A</collab><collab collab-type="author">Linehan WM</collab><collab collab-type="author">Matusik RJ</collab><collab collab-type="author">Price DK</collab><collab collab-type="author">Figg WD</collab><collab collab-type="author">Emmert-Buck MR</collab><collab collab-type="author">Chuaqui RF</collab><year>2005</year><source>Molecular alterations in primary prostate cancer after androgen ablation therapy</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2443">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2443</ext-link><comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE2443)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataset3" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32269" source-id-type="uri"><collab collab-type="author">Stanbrough M</collab><collab collab-type="author">Bubley GJ</collab><collab collab-type="author">Ross K</collab><collab collab-type="author">Golub TR</collab><collab collab-type="author">Rubin MA</collab><collab collab-type="author">Penning TM</collab><collab collab-type="author">Febbo PG</collab><collab collab-type="author">Balk SP</collab><year>2006</year><source>Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32269">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32269</ext-link><comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE32269)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataset4" source-id="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000909.v1.p1" source-id-type="uri"><collab collab-type="author">Beltran H</collab><collab collab-type="author">Prandi D</collab><collab collab-type="author">Mosquera JM</collab><collab collab-type="author">Benelli M</collab><collab collab-type="author">Puca L</collab><collab collab-type="author">Cyrta J</collab><collab collab-type="author">Marotz C</collab><collab collab-type="author">Giannopoulou E</collab><collab collab-type="author">Chakravarthi BV</collab><collab collab-type="author">Varambally S</collab><collab collab-type="author">Tomlins SA</collab><collab collab-type="author">Nanus DM</collab><collab collab-type="author">Tagawa ST</collab><collab collab-type="author">Van Allen EM</collab><collab collab-type="author">Elemento O</collab><collab collab-type="author">Sboner A</collab><collab collab-type="author">Garraway LA9</collab><collab collab-type="author">Rubin MA</collab><collab collab-type="author">Demichelis F</collab><year>2016</year><source>Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000909.v1.p1">https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000909.v1.p1</ext-link><comment>Publicly available at dbGaP (accession no. dbGaP phs000909.v1.p1)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataset5" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67070" source-id-type="uri"><collab collab-type="author">Zhang D</collab><collab collab-type="author">Park D</collab><collab collab-type="author">Zhong Y</collab><collab collab-type="author">Lu Y</collab><collab collab-type="author">Rycaj K</collab><collab collab-type="author">Gong S</collab><collab collab-type="author">Chen X</collab><collab collab-type="author">Liu X</collab><collab collab-type="author">Chao HP</collab><collab collab-type="author">Whitney P</collab><collab collab-type="author">Calhoun-Davis T</collab><collab collab-type="author">Takata Y</collab><collab collab-type="author">Shen J</collab><collab collab-type="author">Iyer VR</collab><collab collab-type="author">Tang DG</collab><year>2016</year><source>Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67070">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67070</ext-link><comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE67070)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataset6" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76724" source-id-type="uri"><collab collab-type="author">Xie Q</collab><collab collab-type="author">Liu Y</collab><collab collab-type="author">Cai T</collab><collab collab-type="author">Horton C</collab><collab collab-type="author">Stefanson J</collab><collab collab-type="author">Wang ZA</collab><year>2017</year><source>Dissecting cell-type-specific roles of androgen receptor in prostate homeostasis and regeneration through lineage tracing</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76724">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76724</ext-link><comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE76724)</comment></related-object></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aytes</surname> <given-names>A</given-names></name><name><surname>Mitrofanova</surname> <given-names>A</given-names></name><name><surname>Kinkade</surname> <given-names>CW</given-names></name><name><surname>Lefebvre</surname> <given-names>C</given-names></name><name><surname>Lei</surname> <given-names>M</given-names></name><name><surname>Phelan</surname> <given-names>V</given-names></name><name><surname>LeKaye</surname> <given-names>HC</given-names></name><name><surname>Koutcher</surname> <given-names>JA</given-names></name><name><surname>Cardiff</surname> <given-names>RD</given-names></name><name><surname>Califano</surname> <given-names>A</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name><name><surname>Abate-Shen</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer</article-title><source>PNAS</source><volume>110</volume><fpage>E3506</fpage><lpage>E3515</lpage><pub-id pub-id-type="doi">10.1073/pnas.1303558110</pub-id><pub-id pub-id-type="pmid">23918374</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baena</surname> <given-names>E</given-names></name><name><surname>Shao</surname> <given-names>Z</given-names></name><name><surname>Linn</surname> <given-names>DE</given-names></name><name><surname>Glass</surname> <given-names>K</given-names></name><name><surname>Hamblen</surname> <given-names>MJ</given-names></name><name><surname>Fujiwara</surname> <given-names>Y</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Nguyen</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Godinho</surname> <given-names>FJ</given-names></name><name><surname>Bronson</surname> <given-names>RT</given-names></name><name><surname>Mucci</surname> <given-names>LA</given-names></name><name><surname>Loda</surname> <given-names>M</given-names></name><name><surname>Yuan</surname> <given-names>GC</given-names></name><name><surname>Orkin</surname> <given-names>SH</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients</article-title><source>Genes &amp; Development</source><volume>27</volume><fpage>683</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1101/gad.211011.112</pub-id><pub-id pub-id-type="pmid">23512661</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banach-Petrosky</surname> <given-names>W</given-names></name><name><surname>Jessen</surname> <given-names>WJ</given-names></name><name><surname>Ouyang</surname> <given-names>X</given-names></name><name><surname>Gao</surname> <given-names>H</given-names></name><name><surname>Rao</surname> <given-names>J</given-names></name><name><surname>Quinn</surname> <given-names>J</given-names></name><name><surname>Aronow</surname> <given-names>BJ</given-names></name><name><surname>Abate-Shen</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice</article-title><source>Cancer Research</source><volume>67</volume><fpage>9089</fpage><lpage>9096</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2887</pub-id><pub-id pub-id-type="pmid">17909013</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beltran</surname> <given-names>H</given-names></name><name><surname>Prandi</surname> <given-names>D</given-names></name><name><surname>Mosquera</surname> <given-names>JM</given-names></name><name><surname>Benelli</surname> <given-names>M</given-names></name><name><surname>Puca</surname> <given-names>L</given-names></name><name><surname>Cyrta</surname> <given-names>J</given-names></name><name><surname>Marotz</surname> <given-names>C</given-names></name><name><surname>Giannopoulou</surname> <given-names>E</given-names></name><name><surname>Chakravarthi</surname> <given-names>BV</given-names></name><name><surname>Varambally</surname> <given-names>S</given-names></name><name><surname>Tomlins</surname> <given-names>SA</given-names></name><name><surname>Nanus</surname> <given-names>DM</given-names></name><name><surname>Tagawa</surname> <given-names>ST</given-names></name><name><surname>Van Allen</surname> <given-names>EM</given-names></name><name><surname>Elemento</surname> <given-names>O</given-names></name><name><surname>Sboner</surname> <given-names>A</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Demichelis</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer</article-title><source>Nature Medicine</source><volume>22</volume><fpage>298</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1038/nm.4045</pub-id><pub-id pub-id-type="pmid">26855148</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beltran</surname> <given-names>H</given-names></name><name><surname>Rickman</surname> <given-names>DS</given-names></name><name><surname>Park</surname> <given-names>K</given-names></name><name><surname>Chae</surname> <given-names>SS</given-names></name><name><surname>Sboner</surname> <given-names>A</given-names></name><name><surname>MacDonald</surname> <given-names>TY</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Sheikh</surname> <given-names>KL</given-names></name><name><surname>Terry</surname> <given-names>S</given-names></name><name><surname>Tagawa</surname> <given-names>ST</given-names></name><name><surname>Dhir</surname> <given-names>R</given-names></name><name><surname>Nelson</surname> <given-names>JB</given-names></name><name><surname>de la Taille</surname> <given-names>A</given-names></name><name><surname>Allory</surname> <given-names>Y</given-names></name><name><surname>Gerstein</surname> <given-names>MB</given-names></name><name><surname>Perner</surname> <given-names>S</given-names></name><name><surname>Pienta</surname> <given-names>KJ</given-names></name><name><surname>Chinnaiyan</surname> <given-names>AM</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Collins</surname> <given-names>CC</given-names></name><name><surname>Gleave</surname> <given-names>ME</given-names></name><name><surname>Demichelis</surname> <given-names>F</given-names></name><name><surname>Nanus</surname> <given-names>DM</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets</article-title><source>Cancer Discovery</source><volume>1</volume><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-11-0130</pub-id><pub-id pub-id-type="pmid">22389870</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beltran</surname> <given-names>H</given-names></name><name><surname>Tomlins</surname> <given-names>S</given-names></name><name><surname>Aparicio</surname> <given-names>A</given-names></name><name><surname>Arora</surname> <given-names>V</given-names></name><name><surname>Rickman</surname> <given-names>D</given-names></name><name><surname>Ayala</surname> <given-names>G</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>True</surname> <given-names>L</given-names></name><name><surname>Gleave</surname> <given-names>ME</given-names></name><name><surname>Soule</surname> <given-names>H</given-names></name><name><surname>Logothetis</surname> <given-names>C</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Aggressive variants of castration-resistant prostate cancer</article-title><source>Clinical Cancer Research</source><volume>20</volume><fpage>2846</fpage><lpage>2850</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-3309</pub-id><pub-id pub-id-type="pmid">24727321</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname> <given-names>CJ</given-names></name><name><surname>Gillespie</surname> <given-names>JW</given-names></name><name><surname>Yi</surname> <given-names>Y</given-names></name><name><surname>Chandramouli</surname> <given-names>GV</given-names></name><name><surname>Perlmutter</surname> <given-names>MA</given-names></name><name><surname>Gathright</surname> <given-names>Y</given-names></name><name><surname>Erickson</surname> <given-names>HS</given-names></name><name><surname>Georgevich</surname> <given-names>L</given-names></name><name><surname>Tangrea</surname> <given-names>MA</given-names></name><name><surname>Duray</surname> <given-names>PH</given-names></name><name><surname>González</surname> <given-names>S</given-names></name><name><surname>Velasco</surname> <given-names>A</given-names></name><name><surname>Linehan</surname> <given-names>WM</given-names></name><name><surname>Matusik</surname> <given-names>RJ</given-names></name><name><surname>Price</surname> <given-names>DK</given-names></name><name><surname>Figg</surname> <given-names>WD</given-names></name><name><surname>Emmert-Buck</surname> <given-names>MR</given-names></name><name><surname>Chuaqui</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Molecular alterations in primary prostate cancer after androgen ablation therapy</article-title><source>Clinical Cancer Research</source><volume>11</volume><fpage>6823</fpage><lpage>6834</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0585</pub-id><pub-id pub-id-type="pmid">16203770</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackwood</surname> <given-names>JK</given-names></name><name><surname>Williamson</surname> <given-names>SC</given-names></name><name><surname>Greaves</surname> <given-names>LC</given-names></name><name><surname>Wilson</surname> <given-names>L</given-names></name><name><surname>Rigas</surname> <given-names>AC</given-names></name><name><surname>Sandher</surname> <given-names>R</given-names></name><name><surname>Pickard</surname> <given-names>RS</given-names></name><name><surname>Robson</surname> <given-names>CN</given-names></name><name><surname>Turnbull</surname> <given-names>DM</given-names></name><name><surname>Taylor</surname> <given-names>RW</given-names></name><name><surname>Heer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells</article-title><source>The Journal of Pathology</source><volume>225</volume><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1002/path.2965</pub-id><pub-id pub-id-type="pmid">21898876</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanpain</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Tracing the cellular origin of cancer</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>126</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1038/ncb2657</pub-id><pub-id pub-id-type="pmid">23334500</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname> <given-names>R</given-names></name><name><surname>Karthaus</surname> <given-names>WR</given-names></name><name><surname>Armenia</surname> <given-names>J</given-names></name><name><surname>Abida</surname> <given-names>W</given-names></name><name><surname>Iaquinta</surname> <given-names>PJ</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Wongvipat</surname> <given-names>J</given-names></name><name><surname>Wasmuth</surname> <given-names>EV</given-names></name><name><surname>Shah</surname> <given-names>N</given-names></name><name><surname>Sullivan</surname> <given-names>PS</given-names></name><name><surname>Doran</surname> <given-names>MG</given-names></name><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Patruno</surname> <given-names>A</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Zheng</surname> <given-names>D</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name><collab>International SU2C/PCF Prostate Cancer Dream Team</collab></person-group><year iso-8601-date="2017">2017</year><article-title>ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis</article-title><source>Nature</source><volume>546</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nature22820</pub-id><pub-id pub-id-type="pmid">28614298</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Chi</surname> <given-names>P</given-names></name><name><surname>Rockowitz</surname> <given-names>S</given-names></name><name><surname>Iaquinta</surname> <given-names>PJ</given-names></name><name><surname>Shamu</surname> <given-names>T</given-names></name><name><surname>Shukla</surname> <given-names>S</given-names></name><name><surname>Gao</surname> <given-names>D</given-names></name><name><surname>Sirota</surname> <given-names>I</given-names></name><name><surname>Carver</surname> <given-names>BS</given-names></name><name><surname>Wongvipat</surname> <given-names>J</given-names></name><name><surname>Scher</surname> <given-names>HI</given-names></name><name><surname>Zheng</surname> <given-names>D</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss</article-title><source>Nature Medicine</source><volume>19</volume><fpage>1023</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1038/nm.3216</pub-id><pub-id pub-id-type="pmid">23817021</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>N</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Ittmann</surname> <given-names>M</given-names></name><name><surname>Xin</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation</article-title><source>Cancer Cell</source><volume>21</volume><fpage>253</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.01.005</pub-id><pub-id pub-id-type="pmid">22340597</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname> <given-names>CW</given-names></name><name><surname>Shibata</surname> <given-names>M</given-names></name><name><surname>Lei</surname> <given-names>M</given-names></name><name><surname>Toivanen</surname> <given-names>R</given-names></name><name><surname>Barlow</surname> <given-names>LJ</given-names></name><name><surname>Bergren</surname> <given-names>SK</given-names></name><name><surname>Badani</surname> <given-names>KK</given-names></name><name><surname>McKiernan</surname> <given-names>JM</given-names></name><name><surname>Benson</surname> <given-names>MC</given-names></name><name><surname>Hibshoosh</surname> <given-names>H</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Single luminal epithelial progenitors can generate prostate organoids in culture</article-title><source>Nature Cell Biology</source><volume>16</volume><fpage>951</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1038/ncb3047</pub-id><pub-id pub-id-type="pmid">25241035</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname> <given-names>GR</given-names></name><name><surname>Ricke</surname> <given-names>W</given-names></name><name><surname>Thomson</surname> <given-names>A</given-names></name><name><surname>Marker</surname> <given-names>PC</given-names></name><name><surname>Risbridger</surname> <given-names>G</given-names></name><name><surname>Hayward</surname> <given-names>SW</given-names></name><name><surname>Wang</surname> <given-names>YZ</given-names></name><name><surname>Donjacour</surname> <given-names>AA</given-names></name><name><surname>Kurita</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development</article-title><source>The Journal of Steroid Biochemistry and Molecular Biology</source><volume>92</volume><fpage>221</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2004.10.017</pub-id><pub-id pub-id-type="pmid">15663986</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Gendt</surname> <given-names>K</given-names></name><name><surname>Swinnen</surname> <given-names>JV</given-names></name><name><surname>Saunders</surname> <given-names>PT</given-names></name><name><surname>Schoonjans</surname> <given-names>L</given-names></name><name><surname>Dewerchin</surname> <given-names>M</given-names></name><name><surname>Devos</surname> <given-names>A</given-names></name><name><surname>Tan</surname> <given-names>K</given-names></name><name><surname>Atanassova</surname> <given-names>N</given-names></name><name><surname>Claessens</surname> <given-names>F</given-names></name><name><surname>Lécureuil</surname> <given-names>C</given-names></name><name><surname>Heyns</surname> <given-names>W</given-names></name><name><surname>Carmeliet</surname> <given-names>P</given-names></name><name><surname>Guillou</surname> <given-names>F</given-names></name><name><surname>Sharpe</surname> <given-names>RM</given-names></name><name><surname>Verhoeven</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis</article-title><source>PNAS</source><volume>101</volume><fpage>1327</fpage><lpage>1332</lpage><pub-id pub-id-type="doi">10.1073/pnas.0308114100</pub-id><pub-id pub-id-type="pmid">14745012</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabregat</surname> <given-names>A</given-names></name><name><surname>Sidiropoulos</surname> <given-names>K</given-names></name><name><surname>Garapati</surname> <given-names>P</given-names></name><name><surname>Gillespie</surname> <given-names>M</given-names></name><name><surname>Hausmann</surname> <given-names>K</given-names></name><name><surname>Haw</surname> <given-names>R</given-names></name><name><surname>Jassal</surname> <given-names>B</given-names></name><name><surname>Jupe</surname> <given-names>S</given-names></name><name><surname>Korninger</surname> <given-names>F</given-names></name><name><surname>McKay</surname> <given-names>S</given-names></name><name><surname>Matthews</surname> <given-names>L</given-names></name><name><surname>May</surname> <given-names>B</given-names></name><name><surname>Milacic</surname> <given-names>M</given-names></name><name><surname>Rothfels</surname> <given-names>K</given-names></name><name><surname>Shamovsky</surname> <given-names>V</given-names></name><name><surname>Webber</surname> <given-names>M</given-names></name><name><surname>Weiser</surname> <given-names>J</given-names></name><name><surname>Williams</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Stein</surname> <given-names>L</given-names></name><name><surname>Hermjakob</surname> <given-names>H</given-names></name><name><surname>D'Eustachio</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Reactome pathway Knowledgebase</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>D481</fpage><lpage>D487</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1351</pub-id><pub-id pub-id-type="pmid">26656494</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Floc'h</surname> <given-names>N</given-names></name><name><surname>Kinkade</surname> <given-names>CW</given-names></name><name><surname>Kobayashi</surname> <given-names>T</given-names></name><name><surname>Aytes</surname> <given-names>A</given-names></name><name><surname>Lefebvre</surname> <given-names>C</given-names></name><name><surname>Mitrofanova</surname> <given-names>A</given-names></name><name><surname>Cardiff</surname> <given-names>RD</given-names></name><name><surname>Califano</surname> <given-names>A</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name><name><surname>Abate-Shen</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model</article-title><source>Cancer Research</source><volume>72</volume><fpage>4483</fpage><lpage>4493</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0283</pub-id><pub-id pub-id-type="pmid">22815528</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaisa</surname> <given-names>NT</given-names></name><name><surname>Graham</surname> <given-names>TA</given-names></name><name><surname>McDonald</surname> <given-names>SA</given-names></name><name><surname>Poulsom</surname> <given-names>R</given-names></name><name><surname>Heidenreich</surname> <given-names>A</given-names></name><name><surname>Jakse</surname> <given-names>G</given-names></name><name><surname>Knuechel</surname> <given-names>R</given-names></name><name><surname>Wright</surname> <given-names>NA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Clonal architecture of human prostatic epithelium in benign and malignant conditions</article-title><source>The Journal of Pathology</source><volume>225</volume><fpage>172</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1002/path.2959</pub-id><pub-id pub-id-type="pmid">21898875</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>N</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Rao</surname> <given-names>MA</given-names></name><name><surname>Case</surname> <given-names>TC</given-names></name><name><surname>Mirosevich</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Jin</surname> <given-names>R</given-names></name><name><surname>Gupta</surname> <given-names>A</given-names></name><name><surname>Rennie</surname> <given-names>PS</given-names></name><name><surname>Matusik</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes</article-title><source>Molecular Endocrinology</source><volume>17</volume><fpage>1484</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1210/me.2003-0020</pub-id><pub-id pub-id-type="pmid">12750453</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germann</surname> <given-names>M</given-names></name><name><surname>Wetterwald</surname> <given-names>A</given-names></name><name><surname>Guzmán-Ramirez</surname> <given-names>N</given-names></name><name><surname>van der Pluijm</surname> <given-names>G</given-names></name><name><surname>Culig</surname> <given-names>Z</given-names></name><name><surname>Cecchini</surname> <given-names>MG</given-names></name><name><surname>Williams</surname> <given-names>ED</given-names></name><name><surname>Thalmann</surname> <given-names>GN</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer</article-title><source>Stem Cells</source><volume>30</volume><fpage>1076</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1002/stem.1087</pub-id><pub-id pub-id-type="pmid">22438320</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname> <given-names>AS</given-names></name><name><surname>Lawson</surname> <given-names>DA</given-names></name><name><surname>Cheng</surname> <given-names>D</given-names></name><name><surname>Sun</surname> <given-names>W</given-names></name><name><surname>Garraway</surname> <given-names>IP</given-names></name><name><surname>Witte</surname> <given-names>ON</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics</article-title><source>PNAS</source><volume>105</volume><fpage>20882</fpage><lpage>20887</lpage><pub-id pub-id-type="doi">10.1073/pnas.0811411106</pub-id><pub-id pub-id-type="pmid">19088204</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurel</surname> <given-names>B</given-names></name><name><surname>Iwata</surname> <given-names>T</given-names></name><name><surname>Koh</surname> <given-names>CM</given-names></name><name><surname>Jenkins</surname> <given-names>RB</given-names></name><name><surname>Lan</surname> <given-names>F</given-names></name><name><surname>Van Dang</surname> <given-names>C</given-names></name><name><surname>Hicks</surname> <given-names>JL</given-names></name><name><surname>Morgan</surname> <given-names>J</given-names></name><name><surname>Cornish</surname> <given-names>TC</given-names></name><name><surname>Sutcliffe</surname> <given-names>S</given-names></name><name><surname>Isaacs</surname> <given-names>WB</given-names></name><name><surname>Luo</surname> <given-names>J</given-names></name><name><surname>De Marzo</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis</article-title><source>Modern Pathology</source><volume>21</volume><fpage>1156</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2008.111</pub-id><pub-id pub-id-type="pmid">18567993</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>HH</given-names></name><name><surname>Meyer</surname> <given-names>CA</given-names></name><name><surname>Shin</surname> <given-names>H</given-names></name><name><surname>Bailey</surname> <given-names>ST</given-names></name><name><surname>Wei</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>K</given-names></name><name><surname>Ni</surname> <given-names>M</given-names></name><name><surname>Lupien</surname> <given-names>M</given-names></name><name><surname>Mieczkowski</surname> <given-names>P</given-names></name><name><surname>Lieb</surname> <given-names>JD</given-names></name><name><surname>Zhao</surname> <given-names>K</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Nucleosome dynamics define transcriptional enhancers</article-title><source>Nature Genetics</source><volume>42</volume><fpage>343</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/ng.545</pub-id><pub-id pub-id-type="pmid">20208536</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Höfner</surname> <given-names>T</given-names></name><name><surname>Eisen</surname> <given-names>C</given-names></name><name><surname>Klein</surname> <given-names>C</given-names></name><name><surname>Rigo-Watermeier</surname> <given-names>T</given-names></name><name><surname>Goeppinger</surname> <given-names>SM</given-names></name><name><surname>Jauch</surname> <given-names>A</given-names></name><name><surname>Schoell</surname> <given-names>B</given-names></name><name><surname>Vogel</surname> <given-names>V</given-names></name><name><surname>Noll</surname> <given-names>E</given-names></name><name><surname>Weichert</surname> <given-names>W</given-names></name><name><surname>Baccelli</surname> <given-names>I</given-names></name><name><surname>Schillert</surname> <given-names>A</given-names></name><name><surname>Wagner</surname> <given-names>S</given-names></name><name><surname>Pahernik</surname> <given-names>S</given-names></name><name><surname>Sprick</surname> <given-names>MR</given-names></name><name><surname>Trumpp</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Defined conditions for the isolation and expansion of basal prostate progenitor cells of mouse and human origin</article-title><source>Stem Cell Reports</source><volume>4</volume><fpage>503</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2015.01.015</pub-id><pub-id pub-id-type="pmid">25702639</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname> <given-names>EL</given-names></name><name><surname>Willis</surname> <given-names>N</given-names></name><name><surname>Mercer</surname> <given-names>K</given-names></name><name><surname>Bronson</surname> <given-names>RT</given-names></name><name><surname>Crowley</surname> <given-names>D</given-names></name><name><surname>Montoya</surname> <given-names>R</given-names></name><name><surname>Jacks</surname> <given-names>T</given-names></name><name><surname>Tuveson</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras</article-title><source>Genes &amp; Development</source><volume>15</volume><fpage>3243</fpage><lpage>3248</lpage><pub-id pub-id-type="doi">10.1101/gad.943001</pub-id><pub-id pub-id-type="pmid">11751630</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karthaus</surname> <given-names>WR</given-names></name><name><surname>Iaquinta</surname> <given-names>PJ</given-names></name><name><surname>Drost</surname> <given-names>J</given-names></name><name><surname>Gracanin</surname> <given-names>A</given-names></name><name><surname>van Boxtel</surname> <given-names>R</given-names></name><name><surname>Wongvipat</surname> <given-names>J</given-names></name><name><surname>Dowling</surname> <given-names>CM</given-names></name><name><surname>Gao</surname> <given-names>D</given-names></name><name><surname>Begthel</surname> <given-names>H</given-names></name><name><surname>Sachs</surname> <given-names>N</given-names></name><name><surname>Vries</surname> <given-names>RGJ</given-names></name><name><surname>Cuppen</surname> <given-names>E</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name><name><surname>Clevers</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of multipotent luminal progenitor cells in human prostate organoid cultures</article-title><source>Cell</source><volume>159</volume><fpage>163</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.08.017</pub-id><pub-id pub-id-type="pmid">25201529</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ku</surname> <given-names>SY</given-names></name><name><surname>Rosario</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Mu</surname> <given-names>P</given-names></name><name><surname>Seshadri</surname> <given-names>M</given-names></name><name><surname>Goodrich</surname> <given-names>ZW</given-names></name><name><surname>Goodrich</surname> <given-names>MM</given-names></name><name><surname>Labbé</surname> <given-names>DP</given-names></name><name><surname>Gomez</surname> <given-names>EC</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Long</surname> <given-names>HW</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Loda</surname> <given-names>M</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name><name><surname>Ellis</surname> <given-names>L</given-names></name><name><surname>Goodrich</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance</article-title><source>Science</source><volume>355</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1126/science.aah4199</pub-id><pub-id pub-id-type="pmid">28059767</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname> <given-names>OJ</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Ittmann</surname> <given-names>MM</given-names></name><name><surname>Xin</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin</article-title><source>PNAS</source><volume>111</volume><fpage>E592</fpage><lpage>E600</lpage><pub-id pub-id-type="doi">10.1073/pnas.1318157111</pub-id><pub-id pub-id-type="pmid">24367088</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname> <given-names>OJ</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Xin</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Stem cell antigen-1 identifies a distinct androgen-independent murine prostatic luminal cell lineage with bipotent potential</article-title><source>Stem Cells</source><volume>34</volume><fpage>191</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/stem.2217</pub-id><pub-id pub-id-type="pmid">26418304</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname> <given-names>DA</given-names></name><name><surname>Xin</surname> <given-names>L</given-names></name><name><surname>Lukacs</surname> <given-names>RU</given-names></name><name><surname>Cheng</surname> <given-names>D</given-names></name><name><surname>Witte</surname> <given-names>ON</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Isolation and functional characterization of murine prostate stem cells</article-title><source>PNAS</source><volume>104</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1073/pnas.0609684104</pub-id><pub-id pub-id-type="pmid">17185413</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>SH</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell types of origin for prostate cancer</article-title><source>Current Opinion in Cell Biology</source><volume>37</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2015.10.002</pub-id><pub-id pub-id-type="pmid">26506127</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>SO</given-names></name><name><surname>Tian</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>CK</given-names></name><name><surname>Ma</surname> <given-names>Z</given-names></name><name><surname>Lai</surname> <given-names>KP</given-names></name><name><surname>Hsiao</surname> <given-names>H</given-names></name><name><surname>Jiang</surname> <given-names>M</given-names></name><name><surname>Yeh</surname> <given-names>S</given-names></name><name><surname>Chang</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Suppressor role of androgen receptor in proliferation of prostate basal epithelial and progenitor cells</article-title><source>Journal of Endocrinology</source><volume>213</volume><fpage>173</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1530/JOE-11-0474</pub-id><pub-id pub-id-type="pmid">22393245</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesche</surname> <given-names>R</given-names></name><name><surname>Groszer</surname> <given-names>M</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Messing</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene</article-title><source>Genesis</source><volume>32</volume><fpage>148</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1002/gene.10036</pub-id><pub-id pub-id-type="pmid">11857804</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Pascal</surname> <given-names>LE</given-names></name><name><surname>Isharwal</surname> <given-names>S</given-names></name><name><surname>Metzger</surname> <given-names>D</given-names></name><name><surname>Ramos Garcia</surname> <given-names>R</given-names></name><name><surname>Pilch</surname> <given-names>J</given-names></name><name><surname>Kasper</surname> <given-names>S</given-names></name><name><surname>Williams</surname> <given-names>K</given-names></name><name><surname>Basse</surname> <given-names>PH</given-names></name><name><surname>Nelson</surname> <given-names>JB</given-names></name><name><surname>Chambon</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regenerated luminal epithelial cells are derived from preexisting luminal epithelial cells in adult mouse prostate</article-title><source>Molecular Endocrinology</source><volume>25</volume><fpage>1849</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1210/me.2011-1081</pub-id><pub-id pub-id-type="pmid">21940754</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>TL</given-names></name><name><surname>Huang</surname> <given-names>YF</given-names></name><name><surname>You</surname> <given-names>LR</given-names></name><name><surname>Chao</surname> <given-names>NC</given-names></name><name><surname>Su</surname> <given-names>FY</given-names></name><name><surname>Chang</surname> <given-names>JL</given-names></name><name><surname>Chen</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice</article-title><source>The American Journal of Pathology</source><volume>182</volume><fpage>975</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2012.11.025</pub-id><pub-id pub-id-type="pmid">23313138</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meeker</surname> <given-names>AK</given-names></name><name><surname>Hicks</surname> <given-names>JL</given-names></name><name><surname>Platz</surname> <given-names>EA</given-names></name><name><surname>March</surname> <given-names>GE</given-names></name><name><surname>Bennett</surname> <given-names>CJ</given-names></name><name><surname>Delannoy</surname> <given-names>MJ</given-names></name><name><surname>De Marzo</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis</article-title><source>Cancer Research</source><volume>62</volume><fpage>6405</fpage><lpage>6409</lpage><pub-id pub-id-type="pmid">12438224</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirosevich</surname> <given-names>J</given-names></name><name><surname>Bentel</surname> <given-names>JM</given-names></name><name><surname>Zeps</surname> <given-names>N</given-names></name><name><surname>Redmond</surname> <given-names>SL</given-names></name><name><surname>D'Antuono</surname> <given-names>MF</given-names></name><name><surname>Dawkins</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Androgen receptor expression of proliferating basal and luminal cells in adult murine ventral prostate</article-title><source>Journal of Endocrinology</source><volume>162</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1677/joe.0.1620341</pub-id><pub-id pub-id-type="pmid">10467225</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moad</surname> <given-names>M</given-names></name><name><surname>Hannezo</surname> <given-names>E</given-names></name><name><surname>Buczacki</surname> <given-names>SJ</given-names></name><name><surname>Wilson</surname> <given-names>L</given-names></name><name><surname>El-Sherif</surname> <given-names>A</given-names></name><name><surname>Sims</surname> <given-names>D</given-names></name><name><surname>Pickard</surname> <given-names>R</given-names></name><name><surname>Wright</surname> <given-names>NA</given-names></name><name><surname>Williamson</surname> <given-names>SC</given-names></name><name><surname>Turnbull</surname> <given-names>DM</given-names></name><name><surname>Taylor</surname> <given-names>RW</given-names></name><name><surname>Greaves</surname> <given-names>L</given-names></name><name><surname>Robson</surname> <given-names>CN</given-names></name><name><surname>Simons</surname> <given-names>BD</given-names></name><name><surname>Heer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Multipotent basal stem cells, maintained in localized proximal niches, support directed long-ranging epithelial flows in human prostates</article-title><source>Cell Reports</source><volume>20</volume><fpage>1609</fpage><lpage>1622</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.07.061</pub-id><pub-id pub-id-type="pmid">28813673</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Benelli</surname> <given-names>M</given-names></name><name><surname>Karthaus</surname> <given-names>WR</given-names></name><name><surname>Hoover</surname> <given-names>E</given-names></name><name><surname>Chen</surname> <given-names>CC</given-names></name><name><surname>Wongvipat</surname> <given-names>J</given-names></name><name><surname>Ku</surname> <given-names>SY</given-names></name><name><surname>Gao</surname> <given-names>D</given-names></name><name><surname>Cao</surname> <given-names>Z</given-names></name><name><surname>Shah</surname> <given-names>N</given-names></name><name><surname>Adams</surname> <given-names>EJ</given-names></name><name><surname>Abida</surname> <given-names>W</given-names></name><name><surname>Watson</surname> <given-names>PA</given-names></name><name><surname>Prandi</surname> <given-names>D</given-names></name><name><surname>Huang</surname> <given-names>CH</given-names></name><name><surname>de Stanchina</surname> <given-names>E</given-names></name><name><surname>Lowe</surname> <given-names>SW</given-names></name><name><surname>Ellis</surname> <given-names>L</given-names></name><name><surname>Beltran</surname> <given-names>H</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Goodrich</surname> <given-names>DW</given-names></name><name><surname>Demichelis</surname> <given-names>F</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer</article-title><source>Science</source><volume>355</volume><fpage>84</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1126/science.aah4307</pub-id><pub-id pub-id-type="pmid">28059768</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogata</surname> <given-names>H</given-names></name><name><surname>Goto</surname> <given-names>S</given-names></name><name><surname>Sato</surname> <given-names>K</given-names></name><name><surname>Fujibuchi</surname> <given-names>W</given-names></name><name><surname>Bono</surname> <given-names>H</given-names></name><name><surname>Kanehisa</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title><source>Nucleic Acids Research</source><volume>27</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1093/nar/27.1.29</pub-id><pub-id pub-id-type="pmid">9847135</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>JH</given-names></name><name><surname>Walls</surname> <given-names>JE</given-names></name><name><surname>Galvez</surname> <given-names>JJ</given-names></name><name><surname>Kim</surname> <given-names>M</given-names></name><name><surname>Abate-Shen</surname> <given-names>C</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name><name><surname>Cardiff</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Prostatic intraepithelial neoplasia in genetically engineered mice</article-title><source>The American Journal of Pathology</source><volume>161</volume><fpage>727</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)64228-9</pub-id><pub-id pub-id-type="pmid">12163397</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rycaj</surname> <given-names>K</given-names></name><name><surname>Tang</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell-of-origin of cancer versus cancer stem cells: assays and interpretations</article-title><source>Cancer Research</source><volume>75</volume><fpage>4003</fpage><lpage>4011</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-0798</pub-id><pub-id pub-id-type="pmid">26292361</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>MM</given-names></name><name><surname>Abate-Shen</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Molecular genetics of prostate cancer: new prospects for old challenges</article-title><source>Genes &amp; Development</source><volume>24</volume><fpage>1967</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.1101/gad.1965810</pub-id><pub-id pub-id-type="pmid">20844012</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname> <given-names>M</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The roots of cancer: stem cells and the basis for tumor heterogeneity</article-title><source>BioEssays</source><volume>35</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1002/bies.201200101</pub-id><pub-id pub-id-type="pmid">23027425</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivas</surname> <given-names>S</given-names></name><name><surname>Watanabe</surname> <given-names>T</given-names></name><name><surname>Lin</surname> <given-names>CS</given-names></name><name><surname>William</surname> <given-names>CM</given-names></name><name><surname>Tanabe</surname> <given-names>Y</given-names></name><name><surname>Jessell</surname> <given-names>TM</given-names></name><name><surname>Costantini</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus</article-title><source>BMC Developmental Biology</source><volume>1</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.1186/1471-213X-1-4</pub-id><pub-id pub-id-type="pmid">11299042</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanbrough</surname> <given-names>M</given-names></name><name><surname>Bubley</surname> <given-names>GJ</given-names></name><name><surname>Ross</surname> <given-names>K</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Penning</surname> <given-names>TM</given-names></name><name><surname>Febbo</surname> <given-names>PG</given-names></name><name><surname>Balk</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer</article-title><source>Cancer Research</source><volume>66</volume><fpage>2815</fpage><lpage>2825</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4000</pub-id><pub-id pub-id-type="pmid">16510604</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gillette</surname> <given-names>MA</given-names></name><name><surname>Paulovich</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talos</surname> <given-names>F</given-names></name><name><surname>Mitrofanova</surname> <given-names>A</given-names></name><name><surname>Bergren</surname> <given-names>SK</given-names></name><name><surname>Califano</surname> <given-names>A</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14662</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14662</pub-id><pub-id pub-id-type="pmid">28429718</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toivanen</surname> <given-names>R</given-names></name><name><surname>Mohan</surname> <given-names>A</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Basal progenitors contribute to repair of the prostate epithelium following induced luminal anoikis</article-title><source>Stem Cell Reports</source><volume>6</volume><fpage>660</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2016.03.007</pub-id><pub-id pub-id-type="pmid">27117783</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toivanen</surname> <given-names>R</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Prostate organogenesis: tissue induction, hormonal regulation and cell type specification</article-title><source>Development</source><volume>144</volume><fpage>1382</fpage><lpage>1398</lpage><pub-id pub-id-type="doi">10.1242/dev.148270</pub-id><pub-id pub-id-type="pmid">28400434</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visvader</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cells of origin in cancer</article-title><source>Nature</source><volume>469</volume><fpage>314</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1038/nature09781</pub-id><pub-id pub-id-type="pmid">21248838</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlachostergios</surname> <given-names>PJ</given-names></name><name><surname>Puca</surname> <given-names>L</given-names></name><name><surname>Beltran</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Emerging variants of castration-resistant prostate cancer</article-title><source>Current Oncology Reports</source><volume>19</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.1007/s11912-017-0593-6</pub-id><pub-id pub-id-type="pmid">28361223</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Kruithof-de Julio</surname> <given-names>M</given-names></name><name><surname>Economides</surname> <given-names>KD</given-names></name><name><surname>Walker</surname> <given-names>D</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Halili</surname> <given-names>MV</given-names></name><name><surname>Hu</surname> <given-names>YP</given-names></name><name><surname>Price</surname> <given-names>SM</given-names></name><name><surname>Abate-Shen</surname> <given-names>C</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A luminal epithelial stem cell that is a cell of origin for prostate cancer</article-title><source>Nature</source><volume>461</volume><fpage>495</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1038/nature08361</pub-id><pub-id pub-id-type="pmid">19741607</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>ZA</given-names></name><name><surname>Mitrofanova</surname> <given-names>A</given-names></name><name><surname>Bergren</surname> <given-names>SK</given-names></name><name><surname>Abate-Shen</surname> <given-names>C</given-names></name><name><surname>Cardiff</surname> <given-names>RD</given-names></name><name><surname>Califano</surname> <given-names>A</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>274</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1038/ncb2697</pub-id><pub-id pub-id-type="pmid">23434823</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>ZA</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Revisiting the concept of cancer stem cells in prostate cancer</article-title><source>Oncogene</source><volume>30</volume><fpage>1261</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.530</pub-id><pub-id pub-id-type="pmid">21119602</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>ZA</given-names></name><name><surname>Toivanen</surname> <given-names>R</given-names></name><name><surname>Bergren</surname> <given-names>SK</given-names></name><name><surname>Chambon</surname> <given-names>P</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Luminal cells are favored as the cell of origin for prostate cancer</article-title><source>Cell Reports</source><volume>8</volume><fpage>1339</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.08.002</pub-id><pub-id pub-id-type="pmid">25176651</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname> <given-names>PA</given-names></name><name><surname>Arora</surname> <given-names>VK</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer</article-title><source>Nature Reviews Cancer</source><volume>15</volume><fpage>701</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1038/nrc4016</pub-id><pub-id pub-id-type="pmid">26563462</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>CT</given-names></name><name><surname>Altuwaijri</surname> <given-names>S</given-names></name><name><surname>Ricke</surname> <given-names>WA</given-names></name><name><surname>Huang</surname> <given-names>SP</given-names></name><name><surname>Yeh</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Niu</surname> <given-names>Y</given-names></name><name><surname>Tsai</surname> <given-names>MY</given-names></name><name><surname>Chang</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor</article-title><source>PNAS</source><volume>104</volume><fpage>12679</fpage><lpage>12684</lpage><pub-id pub-id-type="doi">10.1073/pnas.0704940104</pub-id><pub-id pub-id-type="pmid">17652515</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname> <given-names>Q</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Cai</surname> <given-names>T</given-names></name><name><surname>Horton</surname> <given-names>C</given-names></name><name><surname>Stefanson</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>ZA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dissecting cell-type-specific roles of androgen receptor in prostate homeostasis and regeneration through lineage tracing</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14284</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14284</pub-id><pub-id pub-id-type="pmid">28112153</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cells of origin for cancer: an updated view from prostate cancer</article-title><source>Oncogene</source><volume>32</volume><fpage>3655</fpage><lpage>3663</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.541</pub-id><pub-id pub-id-type="pmid">23178496</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname> <given-names>S</given-names></name><name><surname>Hu</surname> <given-names>YC</given-names></name><name><surname>Wang</surname> <given-names>PH</given-names></name><name><surname>Xie</surname> <given-names>C</given-names></name><name><surname>Xu</surname> <given-names>Q</given-names></name><name><surname>Tsai</surname> <given-names>MY</given-names></name><name><surname>Dong</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>RS</given-names></name><name><surname>Lee</surname> <given-names>TH</given-names></name><name><surname>Chang</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor</article-title><source>The Journal of Experimental Medicine</source><volume>198</volume><fpage>1899</fpage><lpage>1908</lpage><pub-id pub-id-type="doi">10.1084/jem.20031233</pub-id><pub-id pub-id-type="pmid">14676301</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname> <given-names>YA</given-names></name><name><surname>Roh</surname> <given-names>M</given-names></name><name><surname>Naseem</surname> <given-names>AF</given-names></name><name><surname>Lysy</surname> <given-names>B</given-names></name><name><surname>Desouki</surname> <given-names>MM</given-names></name><name><surname>Unno</surname> <given-names>K</given-names></name><name><surname>Abdulkadir</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bmi1 marks distinct castration-resistant luminal progenitor cells competent for prostate regeneration and tumour initiation</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>12943</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms12943</pub-id><pub-id pub-id-type="pmid">27703144</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Kwon</surname> <given-names>OJ</given-names></name><name><surname>Henry</surname> <given-names>G</given-names></name><name><surname>Malewska</surname> <given-names>A</given-names></name><name><surname>Wei</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Brinkley</surname> <given-names>W</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Castro</surname> <given-names>PD</given-names></name><name><surname>Titus</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>R</given-names></name><name><surname>Sayeeduddin</surname> <given-names>M</given-names></name><name><surname>Raj</surname> <given-names>GV</given-names></name><name><surname>Mauck</surname> <given-names>R</given-names></name><name><surname>Roehrborn</surname> <given-names>C</given-names></name><name><surname>Creighton</surname> <given-names>CJ</given-names></name><name><surname>Strand</surname> <given-names>DW</given-names></name><name><surname>Ittmann</surname> <given-names>MM</given-names></name><name><surname>Xin</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Non-Cell-autonomous regulation of prostate epithelial homeostasis by androgen receptor</article-title><source>Molecular Cell</source><volume>63</volume><fpage>976</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.07.025</pub-id><pub-id pub-id-type="pmid">27594448</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Park</surname> <given-names>D</given-names></name><name><surname>Zhong</surname> <given-names>Y</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Rycaj</surname> <given-names>K</given-names></name><name><surname>Gong</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Chao</surname> <given-names>HP</given-names></name><name><surname>Whitney</surname> <given-names>P</given-names></name><name><surname>Calhoun-Davis</surname> <given-names>T</given-names></name><name><surname>Takata</surname> <given-names>Y</given-names></name><name><surname>Shen</surname> <given-names>J</given-names></name><name><surname>Iyer</surname> <given-names>VR</given-names></name><name><surname>Tang</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10798</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10798</pub-id><pub-id pub-id-type="pmid">26924072</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>H</given-names></name><name><surname>Nolley</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Peehl</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Tissue slice grafts: an in vivo model of human prostate androgen signaling</article-title><source>The American Journal of Pathology</source><volume>177</volume><fpage>229</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.090821</pub-id><pub-id pub-id-type="pmid">20472887</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname> <given-names>M</given-names></name><name><surname>Toivanen</surname> <given-names>R</given-names></name><name><surname>Mitrofanova</surname> <given-names>A</given-names></name><name><surname>Floch</surname> <given-names>N</given-names></name><name><surname>Hayati</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Le Magnen</surname> <given-names>C</given-names></name><name><surname>Chester</surname> <given-names>D</given-names></name><name><surname>Mostaghel</surname> <given-names>EA</given-names></name><name><surname>Califano</surname> <given-names>A</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Shen</surname> <given-names>MM</given-names></name><name><surname>Abate-Shen</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer</article-title><source>Cancer Discovery</source><volume>7</volume><fpage>736</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-1174</pub-id><pub-id pub-id-type="pmid">28411207</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.28768.030</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Morrison</surname><given-names>Sean J</given-names></name><role>Reviewing Editor</role><aff id="aff10"><institution>Howard Hughes Medical Institute, University of Texas Southwestern Medical Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Sean Morrison as the Senior and Reviewing Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Androgen receptor is a major regulator essential for prostate development and prostate cancer progression, but its specific roles in prostate stem/progenitor cells are not fully clarified. By using a previous established CARNs mouse model, the current study investigated AR functions in luminal prostate progenitor cells. Although deletion of AR did not affect the progenitor properties of CARNs, loss of AR suppressed tumor formation from PTEN-deleted CARNs. Paradoxically, however, loss of AR promoted tumor aggressiveness in a PTEN-/-Kras+/+ model. Overall, the studies are very well designed and the data are solid. Together, the findings imply that AR may modulate luminal progenitor cells properties including their ability to serve as a cell of origin of prostate cancer.</p><p>1) One major limitation in the study of CARN's is that they can only be defined in the castrated mouse. One cannot label the luminal cell that will survive castration and become the CARN without castration. Thus, all labeling as well as activation of tumorigenic events is done in the castrated state. This is caveat should be explicitly noted in the paper.</p><p>2) Comparing this work with other recent work, one important question is whether and how CARN's are different from bulk luminal cells. AR deletion in bulk luminal cells, whether using Pb-Cre4 or Nkx3-1-CreERT2 in the non-castrated state does not decrease the ability to regress and regenerate or decrease Pten-loss mediated tumorigenesis (Xie, 2017). However, AR deletion in CARN's seems to be a detriment to regeneration and to Pten-loss mediated tumorigenesis. As noted above though, is the difference due to a different luminal cell (CARN vs. bulk) or Pten deletion in the castrated vs. intact state? This question could be answered using a luminal CreERT2 (CK8 or CK18) in castrated or intact mice during tamoxifen injection to delete Pten. If the authors have these mice it would be very helpful to address this. If not, they should discuss this issue.</p><p>3) What is the relative efficiency between AR+ and AR- CARN's in establishing 2D cultures? The authors used AR-floxed mice and compared clones that per chance were AR-deleted vs. intact.</p><p>4) The data demonstrating that AR depletion in PTEN/KRAS results in aggressive NE tumors is not convincing. The data describing &quot;the important difference between the NPK-CARN and NPKA-CARN tumors&quot; is weak and based on &quot;NPKA-CARN tumors contained a low percentage of synaptophysin-positive neuroendocrine cells among total epithelial cells (0.7%, n=3), which was not observed in the NPK-CARN controls (0%, n=3) (<xref ref-type="fig" rid="fig6">Figure 6E, F</xref>). Since these neuroendocrine cells express YFP (<xref ref-type="fig" rid="fig6">Figure 6E</xref>), we conclude that transformed AR-negative CARNs can give rise to neuroendocrine cells&quot;.</p><p>The authors need to do more than this to show focal NE lesions. At least 3 NE markers should be used and the incidence presented more frankly. Being as low as 0.7%, these cells were difficult to detect…did all 3 mice have focal NE lesions? The error bars in <xref ref-type="fig" rid="fig6">Figure 6</xref> are large and suggest that maybe not all mice showed detectable lesions. This is important to know. If this is to be heralded as a new model, a more thorough presentation of the pathology is required/essential. There is no data in the paper that show these tumors were more aggressive and the authors should tone down the claim &quot;that AR down-regulation primes CARNs to serve as a cell of origin for aggressive CRPC with focal neuroendocrine differentiation&quot;. The differentiation of NE cells in prostate tumors is a very hot topic and very confusing right now. It would not be helpful to add to the confusion.</p><p>5) The Introduction focuses entirely on murine prostate stem and progenitor cells with no discussion of the similarities and, importantly, the differences relative to human prostate stem and progenitors. This is problematic in that the authors switch over to the relevance of the issues raised in the present experiments to human prostate cancer, CRPC, and lineage switching to the neuroendocrine phenotype. While unipotent progenitors have been shown in the murine models for basal and luminal progenitors, lineage tracing in human prostate identifies a common precursor for basal, luminal and neuroendocrine cells (e.g. Blackwood, 2011, Gaisa, 2011). In contrast, there is some, but rather limited evidence for CARNs in human prostate. As such, the authors need to expand on these aspects in the present paper and discuss the possibility that the results in the paper may not be directly translated to the human system.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.28768.031</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>1) One major limitation in the study of CARN's is that they can only be defined in the castrated mouse. One cannot label the luminal cell that will survive castration and become the CARN without castration. Thus, all labeling as well as activation of tumorigenic events is done in the castrated state. This is caveat should be explicitly noted in the paper.</p></disp-quote><p>As noted by the reviewer(s), CARNs are defined in the regressed prostate epithelium, and thus all of the in vivoexperiments involve manipulations performed following castration. We agree that this point should be clearly stated, and have added this caveat to the fifth paragraph of the Discussion.</p><disp-quote content-type="editor-comment"><p>2) Comparing this work with other recent work, one important question is whether and how CARN's are different from bulk luminal cells. AR deletion in bulk luminal cells, whether using Pb-Cre4 or Nkx3-1-CreERT2 in the non-castrated state does not decrease the ability to regress and regenerate or decrease Pten-loss mediated tumorigenesis (Xie, 2017). However, AR deletion in CARN's seems to be a detriment to regeneration and to Pten-loss mediated tumorigenesis. As noted above though, is the difference due to a different luminal cell (CARN vs. bulk) or Pten deletion in the castrated vs. intact state? This question could be answered using a luminal CreERT2 (CK8 or CK18) in castrated or intact mice during tamoxifen injection to delete Pten. If the authors have these mice it would be very helpful to address this. If not, they should discuss this issue.</p></disp-quote><p>As discussed in the third and fourth paragraphs of the Discussion, there are several lines of evidence that CARNs differ from bulk luminal cells in the regressed prostate epithelium. However, as noted by the reviewer(s), the effect of AR deletion in CARNs on tumor formation following <italic>Pten</italic> inactivation could in principle be due to differences between CARNs and bulk luminal cells and/or differences due to <italic>Pten</italic> loss in the regressed versus hormonally-intact prostate epithelium. The suggested experiment using an inducible luminal cytokeratin Cre driver for <italic>Pten</italic> deletion in castrated versus intact mice might help distinguish these possibilities, but we believe that this experiment lies beyond the scope of the present study. However, we have revised the Discussion to explicitly discuss this caveat for our interpretation in the Discussion.</p><disp-quote content-type="editor-comment"><p>3) What is the relative efficiency between AR+ and AR- CARN's in establishing 2D cultures? The authors used AR-floxed mice and compared clones that per chance were AR-deleted vs. intact.</p></disp-quote><p>In response to this comment, we have added new experimental data that directly compares the efficiency of AR<sup>+</sup> and AR<sup>–</sup> CARNs in establishing 2-dimensional cell lines. In brief, we sorted 60 single YFP<sup>+</sup> cells from castrated and tamoxifen-treated <italic>Nkx3.1<sup>CreERT2/+</sup>; Ar<sup>flox/Y</sup>; R26RYFP/+</italic> experimental mice into wells of a 96-well plate. We found that 6 cells gave rise to adherent lines, with 4 of these being AR<sup>+</sup> lines that had failed to undergo Cre-mediated recombination, and 2 lines being AR<sup>–</sup> lines. After correcting for the observed 87.1% efficiency of recombination of the AR-floxed allele in vivo(Results, eighth paragraph), the relative efficiency for the AR<sup>–</sup> CARNs compared to AR<sup>+</sup> CARNs is 7.4%. The decreased plating efficiency of AR<sup>–</sup> CARNs is also consistent with the tissue grafting data in <xref ref-type="fig" rid="fig3">Figure 3H</xref>. This experiment is now described in the Results section.</p><disp-quote content-type="editor-comment"><p>4) The data demonstrating that AR depletion in PTEN/KRAS results in aggressive NE tumors is not convincing. The data describing &quot;the important difference between the NPK-CARN and NPKA-CARN tumors&quot; is weak and based on &quot;NPKA-CARN tumors contained a low percentage of synaptophysin-positive neuroendocrine cells among total epithelial cells (0.7%, n=3), which was not observed in the NPK-CARN controls (0%, n=3) (<xref ref-type="fig" rid="fig6">Figure 6E, F</xref>). Since these neuroendocrine cells express YFP (<xref ref-type="fig" rid="fig6">Figure 6E</xref>), we conclude that transformed AR-negative CARNs can give rise to neuroendocrine cells&quot;.</p><p>The authors need to do more than this to show focal NE lesions. At least 3 NE markers should be used and the incidence presented more frankly. Being as low as 0.7%, these cells were difficult to detect…did all 3 mice have focal NE lesions? The error bars in <xref ref-type="fig" rid="fig6">Figure 6</xref> are large and suggest that maybe not all mice showed detectable lesions. This is important to know. If this is to be heralded as a new model, a more thorough presentation of the pathology is required/essential. There is no data in the paper that show these tumors were more aggressive and the authors should tone down the claim &quot;that AR down-regulation primes CARNs to serve as a cell of origin for aggressive CRPC with focal neuroendocrine differentiation&quot;. The differentiation of NE cells in prostate tumors is a very hot topic and very confusing right now. It would not be helpful to add to the confusion.</p></disp-quote><p>We agree with the reviewers that our description of the focal neuroendocrine differentiation in the <italic>NPKA-CARN</italic> tumors was insufficiently detailed. As suggested by the reviewers, we have provided additional quantitation of the synaptophysin-positive cells in the <italic>NPKA-CARN</italic> tumors. These data are now presented for each individual tumor in <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>, which shows that all three tumors contained synaptophysin-positive cells, but to varying degrees, resulting in the relatively large error bar in <xref ref-type="fig" rid="fig6">Figure 6F</xref>. We have also added panels in <xref ref-type="fig" rid="fig6">Figure 6E</xref> showing expression of additional neuroendocrine markers, corresponding to Foxa2 and Chromogranin A, which were observed in all three tumors, supporting the occurrence of focal neuroendocrine differentiation in <italic>NPKA-CARN</italic> tumors. Furthermore, we agree that the text in the Discussion was previously overstated, and have now edited the text to limit our claims to the occurrence of neuroendocrine transdifferentiation in <italic>NPKA-CARN</italic> tumors.</p><disp-quote content-type="editor-comment"><p>5) The Introduction focuses entirely on murine prostate stem and progenitor cells with no discussion of the similarities and, importantly, the differences relative to human prostate stem and progenitors. This is problematic in that the authors switch over to the relevance of the issues raised in the present experiments to human prostate cancer, CRPC, and lineage switching to the neuroendocrine phenotype. While unipotent progenitors have been shown in the murine models for basal and luminal progenitors, lineage tracing in human prostate identifies a common precursor for basal, luminal and neuroendocrine cells (e.g. Blackwood, 2011, Gaisa, 2011). In contrast, there is some, but rather limited evidence for CARNs in human prostate. As such, the authors need to expand on these aspects in the present paper and discuss the possibility that the results in the paper may not be directly translated to the human system.</p></disp-quote><p>We agree that discussion of epithelial progenitors and the potential existence of CARNs in the human prostate is relevant for the interpretation of our findings, and therefore have added a paragraph on this topic in the Discussion. While functional lineage-tracing approaches as performed in genetically-engineered mice are not feasible in human prostate in vivo, lineage-reconstruction studies by analysis of patterns of mitochondrial DNA mutations have yielded insights into potential lineage relationships. As mentioned by the reviewer(s), previous studies have indicated the existence of multipotent epithelial progenitors (Gaisa et al., 2011; Blackwood et al., 2011). Furthermore, recent analyses have provided evidence for multipotent basal progenitors localized to the most proximal region of the prostate as well as more distally located unipotent luminal progenitors (Moad et al.,). Notably, there is also evidence for bipotential luminal progenitors in ex vivostudies of human prostate organoids (Karthaus et al., 2014). Our revised manuscript also cites evidence for the existence of CARN-like cells in studies of human prostate tissue slice culture (Zhao et al.,2010) and prostate tumors (Germann et al.,2012). Thus, we believe that current data favor a general similarity of epithelial lineage relationships in the two species, suggesting that findings deduced from analyses of the mouse prostate may be translatable to the human prostate. These points are now discussed in the fifth paragraph of the Discussion.</p></body></sub-article></article>